

# Three Biomarkers Identified from Serum Proteomic Analysis of Stage Ovarian Cancer

Cancer Research

64, 5882-5890

DOI: [10.1158/0008-5472.can-04-0746](https://doi.org/10.1158/0008-5472.can-04-0746)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An Introduction to High-Throughput Bioinformatics Data. , 2006, , 1-39.		4
2	Differential proteomics: An overview of gel and non-gel based approaches. Briefings in Functional Genomics & Proteomics, 2004, 3, 220-239.	3.8	108
3	Towards discovery-driven translational research in breast cancer. FEBS Journal, 2004, 272, 2-15.	2.2	45
4	Identification of proteins in laser-microdissected small cell numbers by SELDI-TOF and Tandem MS. BMC Biotechnology, 2004, 4, 30.	1.7	28
5	1 Ovarian Carcinoma: An Introduction. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 287-306.	0.0	1
6	Advancing Cancer Biotherapy with Proteomics. Journal of Immunotherapy, 2005, 28, 183-192.	1.2	18
7	1 Identification of Tumor-Specific Genes. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, , 3-21.	0.0	1
8	Expression Patterns of Plasma Proteins in Spontaneously Diabetic Rats after Oral Administration of a Kampo Medicine, Hachimi-jio-gan, Using SELDI ProteinChip Platform. Biological and Pharmaceutical Bulletin, 2005, 28, 1031-1037.	0.6	13
9	Quantitative analysis of the low molecular weight serum proteome using <sup>18</sup> O stable isotope labeling in a lung tumor xenograft mouse model. Journal of the American Society for Mass Spectrometry, 2005, 16, 1221-1230.	1.2	59
10	Proteomic biomarkers that predict the clinical success of rescue cerclage. American Journal of Obstetrics and Gynecology, 2005, 192, 710-718.	0.7	84
11	CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. International Journal of Gynecological Cancer, 2005, 15, 679-691.	1.2	257
12	Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. International Journal of Gynecological Cancer, 2005, 15, 266-273.	1.2	30
13	New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 2005, 15, 274-281.	1.2	424
14	Serum proteomics profilingâ€”a young technology begins to mature. Nature Biotechnology, 2005, 23, 291-292.	9.4	162
15	Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discovery Today, 2005, 10, 965-976.	3.2	97
16	Methods for etiologic and early marker investigations in the PLCO trial. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 592, 147-154.	0.4	125
17	Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends in Parasitology, 2005, 21, 154-157.	1.5	32
18	Retinopathy of prematurity: gone today, here tomorrow?. Clinical and Experimental Ophthalmology, 2005, 33, 339-340.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Prefractionation techniques in proteome analysis: The mining tools of the third millennium. <i>Electrophoresis</i> , 2005, 26, 297-319.	1.3	275
20	Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. <i>International Journal of Cancer</i> , 2005, 115, 783-789.	2.3	173
21	Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 123-126.	0.7	15
22	Current Awareness on Comparative and Functional Genomics. <i>Comparative and Functional Genomics</i> , 2005, 6, 97-112.	2.0	0
23	Mass spectrometry meets medical sciences: making headway in molecular disease diagnostics. <i>Analytical and Bioanalytical Chemistry</i> , 2005, 381, 24-27.	1.9	4
24	Proteomic Profiling in the Sera of Workers Occupationally Exposed to Arsenic and Lead: Identification of Potential Biomarkers. <i>BioMetals</i> , 2005, 18, 603-613.	1.8	37
25	Improving feature detection and analysis of surface-enhanced laser desorption/ionization-time of flight mass spectra. <i>Proteomics</i> , 2005, 5, 2778-2788.	1.3	27
26	Human urine proteome analysis by three separation approaches. <i>Proteomics</i> , 2005, 5, 4994-5001.	1.3	134
27	Recent advances in blood-related proteomics. <i>Proteomics</i> , 2005, 5, 3019-3034.	1.3	173
28	Characterization of serum biomarkers for detection of early stage ovarian cancer. <i>Proteomics</i> , 2005, 5, 4589-4596.	1.3	263
29	A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. <i>Proteomics</i> , 2005, 5, 3343-3352.	1.3	69
30	Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 1624-1636.	0.7	15
32	Biomarkers: Mining the Biofluid Proteome. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 409-418.	2.5	217
33	Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics. <i>Journal of the National Cancer Institute</i> , 2005, 97, 315-319.	3.0	248
34	Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data. <i>Journal of the National Cancer Institute</i> , 2005, 97, 310-314.	3.0	88
35	Possible Detection of Pancreatic Cancer by Plasma Protein Profiling. <i>Cancer Research</i> , 2005, 65, 10613-10622.	0.4	122
36	The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2005, 3, 322-331.	3.8	156
37	Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2005, 4, 16-26.	3.8	102

#	ARTICLE	IF	CITATIONS
38	A proteomic analysis of mammalian preimplantation embryonic development. <i>Reproduction</i> , 2005, 130, 899-905.	1.1	112
39	Analysis of mass spectral serum profiles for biomarker selection. <i>Bioinformatics</i> , 2005, 21, 4039-4045.	1.8	92
40	Rarity gives a charm: evaluation of trace proteins in plasma and serum. <i>Expert Review of Proteomics</i> , 2005, 2, 393-406.	1.3	16
41	The Role of Proteomics in the Diagnosis and Treatment of Ovarian Cancer. <i>Women's Health</i> , 2005, 1, 365-374.	0.7	2
42	Population proteomics: addressing protein diversity in humans. <i>Expert Review of Proteomics</i> , 2005, 2, 315-324.	1.3	45
43	Serum protein markers for early detection of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7677-7682.	3.3	412
44	Modern Approaches to Age-Old Questions About Thyroid Tumors. <i>Thyroid</i> , 2005, 15, 575-582.	2.4	7
45	Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 735-743.	1.5	37
46	Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid. <i>Clinical Cancer Research</i> , 2005, 11, 8312-8320.	3.2	93
47	Bioinformatics approaches in clinical proteomics. <i>Expert Review of Proteomics</i> , 2005, 2, 847-862.	1.3	20
48	Analysis of Mass Spectrometry Profiles of the Serum Proteome. <i>Clinical Chemistry</i> , 2005, 51, 1-2.	1.5	41
49	Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis. <i>Clinical Chemistry</i> , 2005, 51, 1525-1528.	1.5	109
50	Characterisation of protein microheterogeneity and protein complexes using on-chip immunoaffinity purification-mass spectrometry. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2005, 4, 7-15.	3.8	11
51	Possible Prediction of Chemoradiosensitivity of Esophageal Cancer by Serum Protein Profiling. <i>Clinical Cancer Research</i> , 2005, 11, 8042-8047.	3.2	47
52	SELDI-TOF-MS proteomics of breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 1314-20.	1.4	52
53	Quality control for SELDI analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 125-6.	1.4	11
54	Differential exoprotease activities confer tumor-specific serum peptidome patterns. <i>Journal of Clinical Investigation</i> , 2005, 116, 271-284.	3.9	683
55	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. <i>Journal of Clinical Investigation</i> , 2005, 116, 174-181.	3.9	91

#	ARTICLE	IF	CITATIONS
56	Protein profiling as a diagnostic tool in clinical chemistry: a review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 1281-90.	1.4	32
57	Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery. <i>Expert Review of Proteomics</i> , 2005, 2, 139-145.	1.3	49
58	SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. <i>Pharmacogenomics</i> , 2005, 6, 647-653.	0.6	45
59	Proteomics in the Forefront of Cancer Biomarker Discovery. <i>Journal of Proteome Research</i> , 2005, 4, 1098-1103.	1.8	40
60	Molecular Markers of Early Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4524-4531.	0.8	212
61	IDENTIFICATION OF 2 SERUM BIOMARKERS OF RENAL CELL CARCINOMA BY SURFACE ENHANCED LASER DESORPTION/IONIZATION MASS SPECTROMETRY. <i>Journal of Urology</i> , 2005, 174, 1213-1217.	0.2	27
62	Identification of Protein Fragments as Pattern Features in MALDI-MS Analyses of Serum. <i>Journal of Proteome Research</i> , 2005, 4, 1672-1680.	1.8	19
63	Mass Spectrometry in Diagnostic Oncoproteomics. <i>Cancer Investigation</i> , 2005, 23, 465-478.	0.6	25
64	Applying Proteomics in Clinical Trials. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 141-148.	3.3	19
65	Analysis of MALDI-TOF Serum Profiles for Biomarker Selection and Sample Classification. , 2005, , .		8
66	Direct Tandem Mass Spectrometry Reveals Limitations in Protein Profiling Experiments for Plasma Biomarker Discovery. <i>Journal of Proteome Research</i> , 2005, 4, 972-981.	1.8	210
67	Characterization of Pepsinogen C as a Potential Biomarker for Gastric Cancer Using a Histo-Proteomic Approach. <i>Journal of Proteome Research</i> , 2005, 4, 1799-1804.	1.8	58
68	Gel-Based Versus Gel-Free Proteomics: A Review. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2005, 8, 669-677.	0.6	149
69	Cancer proteomics: many technologies, one goal. <i>Expert Review of Proteomics</i> , 2005, 2, 693-703.	1.3	28
70	Place of Pattern in Proteomic Biomarker Discovery. <i>Journal of Proteome Research</i> , 2005, 4, 1143-1154.	1.8	81
71	Proteomic patterns: their potential for disease diagnosis. <i>Molecular and Cellular Endocrinology</i> , 2005, 230, 95-106.	1.6	175
72	Proteome analysis in the clinical chemistry laboratory: Myth or reality?. <i>Clinica Chimica Acta</i> , 2005, 357, 123-139.	0.5	99
73	The clinical application of proteomics. <i>Clinica Chimica Acta</i> , 2005, 357, 151-158.	0.5	78

#	ARTICLE	IF	CITATIONS
75	Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. <i>BMC Cancer</i> , 2005, 5, 133.	1.1	57
76	SELDI-TOF-MS ProteinChip Array Profiling of Tears from Patients with Dry Eye. , 2005, 46, 863.		189
77	Characterization of Proteins in Human Pancreatic Cancer Serum Using Differential Gel Electrophoresis and Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2005, 4, 1742-1751.	1.8	144
78	Emerging role of inhibin as a biomarker for ovarian cancer. <i>Women's Health</i> , 2005, 1, 51-57.	0.7	5
79	Proteomics in Gynecologic Malignancies. <i>American Journal of Cancer</i> , 2006, 5, 299-317.	0.4	0
80	Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery. <i>Journal of Proteome Research</i> , 2006, 5, 2947-2955.	1.8	38
81	A Serum Proteomic Pattern for the Detection of Colorectal Adenocarcinoma Using Surface Enhanced Laser Desorption and Ionization Mass Spectrometry. <i>Cancer Investigation</i> , 2006, 24, 747-753.	0.6	55
82	Comparison of Software Tools to Improve the Detection of Carcinogen Induced Changes in the Rat Liver Proteome by Analyzing SELDI-TOF <sup>®</sup> MS Spectra. <i>Journal of Proteome Research</i> , 2006, 5, 254-261.	1.8	25
83	Molecular Biomarkers for Cancer Detection in Blood and Bodily Fluids. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 497-560.	2.7	24
84	Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics. <i>Advances in Cancer Research</i> , 2006, 96, 23-50.	1.9	64
85	Proteomic patterns for cancer diagnosis—promise and challenges. <i>Molecular BioSystems</i> , 2006, 2, 358-363.	2.9	9
86	Proteomics of Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1772-1786.	2.5	72
87	Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1957-1967.	2.5	196
88	Seldi-tof MS Profiling of Plasma Proteins in Ovarian Cancer. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2006, 45, 26-32.	0.5	20
89	Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. <i>Lancet</i> , The, 2006, 368, 1012-1021.	6.3	240
90	Strategies for plasma proteomic profiling of cancers. <i>Proteomics</i> , 2006, 6, 5662-5673.	1.3	73
91	Clinical Considerations on the Perspectives in Renal Tumour Molecular Pathology. <i>European Urology Supplements</i> , 2006, 5, 566-572.	0.1	0
92	Elevated Levels of Phosphorylated Fibrinogen- $\alpha$ -Isoforms and Differential Expression of Other Post-Translationally Modified Proteins in the Plasma of Ovarian Cancer Patients. <i>Journal of Proteome Research</i> , 2006, 5, 3318-3325.	1.8	49

#	ARTICLE	IF	CITATIONS
94	Increased Serum Levels of Complement C3a Anaphylatoxin Indicate the Presence of Colorectal Tumors. <i>Gastroenterology</i> , 2006, 131, 1020-1029.	0.6	84
95	Proteomics and heart disease: identifying biomarkers of clinical utility. <i>Expert Review of Proteomics</i> , 2006, 3, 237-249.	1.3	51
96	Protein expression profiling of postmortem brain in schizophrenia. <i>Schizophrenia Research</i> , 2006, 84, 204-213.	1.1	19
97	Discovery and Identification of Potential Biomarkers in a Prospective Study of Chronic Lymphoid Malignancies Using SELDI-TOF MS. <i>Journal of Proteome Research</i> , 2006, 5, 2258-2269.	1.8	46
98	Multiple Gene Expression Analyses in Paraffin-Embedded Tissues by TaqMan Low-Density Array. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 76-83.	1.2	76
99	Advances, Challenges, and Limitations in Serum-Proteome-Based Cancer Diagnosis. <i>Journal of Proteome Research</i> , 2006, 5, 19-25.	1.8	77
100	Molecular Screening of Cancer. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 221-230.	1.6	10
101	Identification of the SELDI ProteinChip Human Serum Retentate by Microcapillary Liquid Chromatography-Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2006, 5, 2207-2216.	1.8	20
102	Nanoporous Surfaces as Harvesting Agents for Mass Spectrometric Analysis of Peptides in Human Plasma. <i>Journal of Proteome Research</i> , 2006, 5, 1261-1266.	1.8	71
103	Proteomic analysis of individual human embryos to identify novel biomarkers of development and viability. <i>Fertility and Sterility</i> , 2006, 85, 101-107.	0.5	138
104	ProteinChip <sup>®</sup> ProteinChip (Ciphergen Biosystems, Inc., Fremont, CA). technology is a useful method in the pathogenesis and diagnosis of endometriosis: a preliminary study. <i>Fertility and Sterility</i> , 2006, 86, 203-209.	0.5	42
105	Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. <i>Clinica Chimica Acta</i> , 2006, 366, 249-256.	0.5	32
107	Clinical proteomics and mass spectrometry profiling for cancer detection. <i>Expert Review of Proteomics</i> , 2006, 3, 311-320.	1.3	43
108	Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 251-259.	4.0	177
109	Diagnostic Proteomics. , 2006, , 247-276.		0
110	Multi-Marker Testing for Cancer: What can we Learn from Modern Prenatal Testing for Trisomy-21. <i>Cancer Informatics</i> , 2006, 2, 117693510600200.	0.9	2
111	A List of Candidate Cancer Biomarkers for Targeted Proteomics. <i>Biomarker Insights</i> , 2006, 1, 117727190600100.	1.0	69
112	Ovarian Cancer Screening. , 2006, , 47-68.		1

#	ARTICLE	IF	CITATIONS
113	Analysis of Human Proteins that Have an Affinity to Heavy Metals by Metal-Chelating Column Chromatography. <i>Industrial Health</i> , 2006, 44, 674-678.	0.4	4
115	SELDI-TOF MS serum protein profiles in breast cancer: Assessment of robustness and validity. <i>Cancer Biomarkers</i> , 2006, 2, 235-248.	0.8	14
116	Proteomics Success Story. Towards Early Detection of Breast and Ovarian Cancer: Plasma Proteomics as a Tool to Find Novel Markers. <i>Proteomics</i> , 2006, 6, 65-68.	1.3	8
117	Convergence of the proteomic pattern in cancer. <i>Bioinformatics</i> , 2006, 22, 1293-1296.	1.8	6
118	Screening for Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2006, 49, 433-447.	0.6	69
119	Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. <i>Proteomics</i> , 2006, 6, 2600-2608.	1.3	44
120	Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. <i>Proteomics</i> , 2006, 6, 3426-3435.	1.3	50
121	Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. <i>Proteomics</i> , 2006, 6, 2286-2294.	1.3	52
122	Proteomic characterization of inter-alpha inhibitor proteins from human plasma. <i>Proteomics</i> , 2006, 6, 2874-2885.	1.3	72
123	Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. <i>Proteomics</i> , 2006, 6, 3243-3250.	1.3	84
124	Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. <i>Proteomics</i> , 2006, 6, 5880-5890.	1.3	56
125	A novel approach and protocol for discovering extremely low-abundance proteins in serum. <i>Proteomics</i> , 2006, 6, 4845-4855.	1.3	49
126	Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. <i>Proteomics</i> , 2006, 6, 5344-5349.	1.3	45
127	Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. <i>Proteomics</i> , 2006, 6, 5183-5192.	1.3	63
128	Human body fluid proteome analysis. <i>Proteomics</i> , 2006, 6, 6326-6353.	1.3	488
129	Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biomarkers. <i>Proteomics</i> , 2006, 6, 6124-6133.	1.3	10
130	Plasma proteomic pattern as biomarkers for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 139-146.	1.2	42
131	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 152-165.	1.2	48



#	ARTICLE	IF	CITATIONS
132	Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1216-1224.	1.2	27
133	Methodology in plasma proteomic pattern experiments. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1951-1952.	1.2	0
134	The blood peptidome: a higher dimension of information content for cancer biomarker discovery. <i>Nature Reviews Cancer</i> , 2006, 6, 961-967.	12.8	322
135	Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. <i>Biochemistry (Moscow)</i> , 2006, 71, 354-360.	0.7	47
136	Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. <i>British Journal of Cancer</i> , 2006, 94, 287-292.	2.9	62
137	Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion. <i>Laboratory Investigation</i> , 2006, 86, 951-958.	1.7	17
138	Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. <i>Oncogene</i> , 2006, 25, 981-989.	2.6	112
139	Molecular predictors of response and outcome in ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 19-37.	2.0	36
140	The amplified peptidome: the new treasure chest of candidate biomarkers. <i>Current Opinion in Chemical Biology</i> , 2006, 10, 50-55.	2.8	80
141	Proteomic technology for biomarker profiling in cancer: an update. <i>Journal of Zhejiang University: Science B</i> , 2006, 7, 411-420.	1.3	42
142	Mass Spectrometry-Based Study of the Plasma Proteome in a Mouse Intestinal Tumor Model. <i>Journal of Proteome Research</i> , 2006, 5, 1866-1878.	1.8	35
143	Clinical proteomics. <i>Clinical Proteomics</i> , 2006, 2, 1-4.	1.1	3
144	The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome. <i>Clinical Chemistry</i> , 2006, 52, 1223-1237.	1.5	327
145	Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 744-755.	1.4	99
146	A Review and an Update on the Screening of Epithelial Ovarian Cancer. <i>Current Problems in Cancer</i> , 2006, 30, 203-232.	1.0	11
147	Contributions of advanced proteomics technologies to cancer diagnosis. <i>Clinical and Translational Oncology</i> , 2006, 8, 566-580.	1.2	37
148	Proteomic analysis in cancer research: potential application in clinical use. <i>Clinical and Translational Oncology</i> , 2006, 8, 250-261.	1.2	33
149	Cancer proteomics. <i>Clinical Proteomics</i> , 2006, 2, 129-132.	1.1	0

#	ARTICLE	IF	CITATIONS
150	Comparison between surface and bead-based MALDI profiling technologies using a single bioinformatics algorithm. <i>Clinical Proteomics</i> , 2006, 2, 145-152.	1.1	1
151	Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 247-253.	0.6	40
152	Familial ovarian cancer screening. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 321-338.	1.4	16
153	The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. <i>Translational Research</i> , 2006, 147, 83-90.	2.4	83
154	Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. <i>Electrophoresis</i> , 2006, 27, 1641-1650.	1.3	121
155	Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. <i>Cancer</i> , 2006, 107, 99-107.	2.0	37
156	Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. <i>International Journal of Cancer</i> , 2006, 118, 412-421.	2.3	69
157	From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 1750-1758.	2.3	49
158	Quantification of Fragments of Human Serum Inter- $\alpha$ -Trypsin Inhibitor Heavy Chain 4 by a Surface-Enhanced Laser Desorption/Ionization-Based Immunoassay. <i>Clinical Chemistry</i> , 2006, 52, 1045-1053.	1.5	97
159	APO-AII IS AN ELEVATED BIOMARKER OF CHRONIC NON-HUMAN PRIMATE ETHANOL SELF-ADMINISTRATION. <i>Alcohol and Alcoholism</i> , 2006, 41, 300-305.	0.9	17
160	Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer. <i>Women's Health</i> , 2006, 2, 141-158.	0.7	4
161	Multiple biomarker panels for early detection of ovarian cancer. <i>Future Oncology</i> , 2006, 2, 733-741.	1.1	40
162	Biomarkers for the Development of Cancer Vaccines. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 337-343.	1.6	15
163	Translating genomic biomarkers into clinically useful diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 179-191.	1.5	51
164	Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine. <i>Clinical Cancer Research</i> , 2006, 12, 432-441.	3.2	147
165	Application of SELDI-TOF-MS in protein profiling: Promises and pitfalls. <i>Journal of Medical Biochemistry</i> , 2006, 25, 201-210.	0.1	1
166	From bio-molecular and technology innovations to clinical practice: focus on ovarian cancer. <i>Annals of Oncology</i> , 2006, 17, vii46-vii48.	0.6	3
167	Biomarker Discovery by Imaging Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1876-1886.	2.5	128

#	ARTICLE	IF	CITATIONS
168	Ovarian Cancer Biomarkers in Urine. <i>Clinical Cancer Research</i> , 2006, 12, 323-327.	3.2	33
169	Population Proteomics. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1811-1818.	2.5	73
170	Finding regions of significance in SELDI measurements for identifying protein biomarkers. <i>Bioinformatics</i> , 2006, 22, 1515-1523.	1.8	39
171	Protein profile study of clinical samples of ovarian cancer using high-performance liquid chromatography-laser induced fluorescence (HPLC-LIF). , 2006, 6092, 149.		8
172	Proteohistographyâ€œDirect Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 13-17.	1.3	20
173	Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1243-52.	1.4	49
174	Pretreatment of Serum with Penicillamine: Effects on Capillary Electrophoresis Patterns and on Immunonephelometric Measurement of Immunoglobulins. <i>Clinical Chemistry</i> , 2006, 52, 772-774.	1.5	1
175	Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry: Some of the authors of the article cited above respond:. <i>Clinical Chemistry</i> , 2006, 52, 772-772.	1.5	2
176	Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines. <i>Cancer Research</i> , 2006, 66, 1376-1383.	0.4	24
177	Isolation of a Natural Inhibitor of Human Malignant Glial Cell Invasion: Inter Î±-Trypsin Inhibitor Heavy Chain 2. <i>Cancer Research</i> , 2006, 66, 1464-1472.	0.4	30
178	A Swarm Intelligence Based Algorithm for Proteomic Pattern Detection of Ovarian Cancer. , 2006, , .		10
179	Perspectives of proteomics in acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1663-1675.	1.1	9
180	Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry. <i>Clinical Chemistry</i> , 2006, 52, 771-772.	1.5	16
181	Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1641-1646.	1.1	85
182	A ROBUST BIOMARKER DISCOVERY PIPELINE FOR HIGH-PERFORMANCE MASS SPECTROMETRY DATA. <i>Journal of Bioinformatics and Computational Biology</i> , 2007, 05, 1023-1045.	0.3	8
183	From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1307-1312.	3.3	91
184	A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples. <i>Clinical Chemistry</i> , 2007, 53, 1067-1074.	1.5	113
185	No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. <i>British Journal of Cancer</i> , 2007, 96, 1335-1342.	2.9	134

#	ARTICLE	IF	CITATIONS
186	Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Review of Proteomics, 2007, 4, 51-65.	1.3	138
187	Exploiting inter-gene information for microarray data integration. , 2007, , .		5
188	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry, 2007, 53, 645-656.	1.5	131
189	Proteins' promise â€“ progress and challenges in ovarian cancer proteomics. Menopause International, 2007, 13, 148-153.	1.6	2
190	Intersession reproducibility of mass spectrometry profiles and its effect on accuracy of multivariate classification models. Bioinformatics, 2007, 23, 3065-3072.	1.8	15
191	Protein Expression within the Human Renal Cortex and Renal Cell Carcinoma: The Implication of Cold Ischemia. Cell Preservation Technology, 2007, 5, 85-92.	0.8	1
192	Cancer Biomarker Discovery in Plasma Using a Tissue-targeted Proteomic Approach. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1915-1917.	1.1	41
193	Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1954-1965.	1.1	161
195	Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptorâ€™pituitary tumor transforming gene transgenic mice. Journal of Endocrinology, 2007, 194, 179-191.	1.2	13
196	ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma. Clinical Chemistry, 2007, 53, 241-250.	1.5	50
197	Nutritional Proteomics: Methods and Concepts for Research in Nutritional Science. Annals of Nutrition and Metabolism, 2007, 51, 99-107.	1.0	30
198	Coagulation and Complement Protein Differences Between Septic and Uninfected Systemic Inflammatory Response Syndrome Patients. Journal of Trauma, 2007, 62, 1082-1094.	2.3	20
199	Protein Expression Profiling Reveals Distinctive Changes in Serum Proteins Associated With Chronic Pancreatitis. Pancreas, 2007, 35, 334-342.	0.5	18
200	Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling. Pancreas, 2007, 34, 205-214.	0.5	132
201	Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respiratory Medicine, 2007, 101, 1687-1695.	1.3	46
202	Proteomic distinction between humans and great apes based on plasma transthyretin microheterogeneity. Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 2007, 2, 144-149.	0.4	2
203	Enzymes and related proteins as cancer biomarkers: A proteomic approach. Clinica Chimica Acta, 2007, 381, 93-97.	0.5	61
204	How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. Journal of Clinical Epidemiology, 2007, 60, 1205-1219.	2.4	154

#	ARTICLE	IF	CITATIONS
206	Clinical Chemistry of the Laboratory Mouse. , 2007, , 171-216.		16
207	Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides. Neoplasia, 2007, 9, 254-259.	2.3	35
209	Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Review of Proteomics, 2007, 4, 121-131.	1.3	18
210	Conventional and Proteomic Technologies for the Detection of Early Stage Malignancies: Markers for Ovarian Cancer. Critical Reviews in Clinical Laboratory Sciences, 2007, 44, 87-114.	2.7	12
212	A cancer protein microarray platform using antibody fragments and its clinical applications. Molecular BioSystems, 2007, 3, 151-158.	2.9	25
213	Proteomic analysis of human thyroid fine needle aspiration fluid. Journal of Endocrinological Investigation, 2007, 30, 865-869.	1.8	14
214	Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1435-49.	1.4	80
215	Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer, 2007, 6, 25.	7.9	212
216	Epithelial Ovarian Cancer: Disease Etiology, Treatment, Detection, and Investigational Gene, Metabolite, and Protein Biomarkers. Journal of Proteome Research, 2007, 6, 2936-2962.	1.8	102
217	Comprehensive Peptidome Analysis of Mouse Livers by Size Exclusion Chromatography Prefractionation and NanoLC-MS/MS Identification. Journal of Proteome Research, 2007, 6, 801-808.	1.8	42
219	Peritoneal Fluid Cytokines and the Differential Diagnosis of Benign and Malignant Ovarian Tumors and Residual/Recurrent Disease Examination. International Journal of Biological Markers, 2007, 22, 172-180.	0.7	14
220	Early Detection of Ovarian Cancer. Disease Markers, 2007, 23, 397-410.	0.6	223
221	Proteomics as a Tool for Biomarker Discovery. Disease Markers, 2007, 23, 411-417.	0.6	41
222	Proteomics and Mass Spectrometry for Cancer Biomarker Discovery. Biomarker Insights, 2007, 2, 117727190700200.	1.0	10
223	Comparison of Supervised Classification Methods for Protein Profiling in Cancer Diagnosis. Cancer Informatics, 2007, 3, 117693510700300.	0.9	6
225	Identifying Biomarkers from Mass Spectrometry Data with Ordinal Outcome. Cancer Informatics, 2007, 3, 117693510700300.	0.9	9
226	Ovarian Cancer and Its Detection. , 2007, , 593-598.		0
227	Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection. Biomarker Insights, 2007, 2, 117727190700200.	1.0	45

#	ARTICLE	IF	CITATIONS
228	Diagnostic Application of Serum Proteomic Patterns in Gastric Cancer Patients by ProteinChip Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. International Journal of Biological Markers, 2007, 22, 281-286.	0.7	15
229	Toxicogenomics and Systems Toxicology. , 0, , 99-150.		0
231	Statistical Methods for Biomarker Discovery Using Mass Spectrometry. , 0, , 465-486.		2
233	SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. International Journal of Cancer, 2007, 121, 615-620.	2.3	31
234	Protein microchips in biomedicine and biomarker discovery. Electrophoresis, 2007, 28, 4261-4273.	1.3	69
235	Mass spectrometry-based proteomics technologies in cancer diagnostics. Mass Spectrometry Reviews, 2007, 26, 403-431.	2.8	98
236	Comparative profiling of human saliva by intact protein LC/ESI-TOF mass spectrometry. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 897-906.	1.1	26
237	Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. Journal of Chromatography A, 2007, 1153, 259-276.	1.8	170
238	Functional identification of novel activities: Activity-based selection of proteins from complete proteomes. Analytical Biochemistry, 2007, 365, 91-102.	1.1	4
239	Biomarker discovery from body fluids using mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 849, 105-114.	1.2	45
240	Cardiovascular proteomic analysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 855, 28-34.	1.2	7
241	Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics - Clinical Applications, 2007, 1, 107-117.	0.8	32
242	Proteomics in human cancer research. Proteomics - Clinical Applications, 2007, 1, 4-17.	0.8	25
243	Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics - Clinical Applications, 2007, 1, 536-544.	0.8	15
244	Large-scale protein identification of human urine proteome by multi-dimensional LC and MS/MS. Proteomics - Clinical Applications, 2007, 1, 577-587.	0.8	16
245	Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera. Proteomics - Clinical Applications, 2007, 1, 1605-1612.	0.8	11
246	A better understanding of molecular mechanisms underlying human disease. Proteomics - Clinical Applications, 2007, 1, 983-1003.	0.8	18
247	Proteomics in ocular fluids. Proteomics - Clinical Applications, 2007, 1, 876-888.	0.8	70

#	ARTICLE	IF	CITATIONS
248	Markers of breast and gynecological malignancies: The clinical approach of proteomics-based studies. <i>Proteomics - Clinical Applications</i> , 2007, 1, 1090-1101.	0.8	5
249	Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. <i>Proteomics</i> , 2007, 7, 4045-4052.	1.3	15
250	Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers. <i>Proteomics</i> , 2007, 7, 3980-3991.	1.3	33
251	Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. <i>Laboratory Investigation</i> , 2007, 87, 161-172.	1.7	45
252	Development of an enhanced proteomic method to detect prognostic and diagnostic markers of healing in chronic wound fluid. <i>British Journal of Dermatology</i> , 2008, 158, 281-290.	1.4	41
253	Diagnosis of gastric cancer using decision tree classification of mass spectral data. <i>Cancer Science</i> , 2007, 98, 37-43.	1.7	73
254	Reduced transthyretin expression in sera of lung cancer. <i>Cancer Science</i> , 2007, 98, 1617-1624.	1.7	46
255	Clinical trials in gynecological cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 547-556.	1.2	9
256	Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. <i>Gynecologic Oncology</i> , 2007, 107, 58-65.	0.6	93
257	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. <i>Seminars in Oncology</i> , 2007, 34, 303-310.	0.8	89
258	1,2-propanediol and the type of cryopreservation procedure adversely affect mouse oocyte physiology. <i>Human Reproduction</i> , 2007, 22, 250-259.	0.4	110
259	Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2470-2476.	0.7	78
261	Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 825-834.	1.2	32
262	Contemporary progress in ovarian cancer screening. <i>Current Oncology Reports</i> , 2007, 9, 485-493.	1.8	3
263	Proteomic Profiling of Ovarian Cancer Plasma using Immunoaffinity Depleted Plasma and Two-Dimensional PAGE. <i>Clinical Proteomics</i> , 2007, 3, 22-29.	1.1	2
264	Comprehensive proteomic analysis of the human milk proteome: Contribution of protein fractionation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 876, 252-256.	1.2	46
266	Proteomics, a new tool to monitor cancer therapy?. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 129-136.	0.3	2
267	Diagnosis of tumor-like polypoid lesions of gallbladder by serum proteomic fingerprint. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2008, 20, 286-289.	0.7	0

#	ARTICLE	IF	CITATIONS
268	Application of proteome technology in screening biomarkers associated with gastric cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 394-397.	0.1	1
269	Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. BMC Medical Genomics, 2008, 1, 4.	0.7	6
270	The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Medical Genomics, 2008, 1, 54.	0.7	37
271	Immobilization strategies for single-chain antibody microarrays. Proteomics, 2008, 8, 2199-2210.	1.3	26
272	Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Communications in Mass Spectrometry, 2008, 22, 2915-2928.	0.7	21
273	Ovarian cancer proteomics: Many technologies one goal. Proteomics - Clinical Applications, 2008, 2, 195-218.	0.8	13
274	Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics - Clinical Applications, 2008, 2, 936-945.	0.8	26
275	Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics - Clinical Applications, 2008, 2, 543-555.	0.8	21
276	Bringing diagnostic technologies to the clinical laboratory: Rigor, regulation, and reality. Proteomics - Clinical Applications, 2008, 2, 1378-1385.	0.8	10
277	Identification of apolipoprotein CIII as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection. Proteomics - Clinical Applications, 2008, 2, 751-761.	0.8	9
278	Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis, 2008, 29, 2645-2650.	1.3	42
279	Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. Journal of Proteomics, 2008, 71, 168-175.	1.2	110
280	Cytokine elevations in acute coronary syndrome and ovarian cancer: A mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clinical Biochemistry, 2008, 41, 607-610.	0.8	16
281	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	1.5	539
282	Molecular Mechanisms and Potential Clinical Significance of S-Glutathionylation. Antioxidants and Redox Signaling, 2008, 10, 445-474.	2.5	275
283	Serum Biomarker Profile Associated With High Bone Turnover and BMD in Postmenopausal Women. Journal of Bone and Mineral Research, 2008, 23, 1106-1117.	3.1	41
284	Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. American Journal of Obstetrics and Gynecology, 2008, 198, 553.e1-553.e6.	0.7	24
285	The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?. American Journal of Obstetrics and Gynecology, 2008, 199, 215-223.	0.7	250



#	ARTICLE	IF	CITATIONS
286	Marqueurs tumoraux: utilisation clinique en 2008 et avancées récentes. Revue Francophone Des Laboratoires, 2008, 2008, 23-26.	0.0	0
287	The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene, 2008, 27, 865-876.	2.6	75
288	Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. British Journal of Cancer, 2008, 99, 1103-1113.	2.9	90
289	Serum biomarker profiling in cancer studies: a question of standardisation?. Veterinary and Comparative Oncology, 2008, 6, 224-247.	0.8	18
290	Ovarian cancer in the proteomics era. International Journal of Gynecological Cancer, 2008, 18, 1-6.	1.2	34
291	Serum proteomic patterns for ovarian cancer monitoring. International Journal of Gynecological Cancer, 2008, 18, 985-995.	1.2	19
292	Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecologic Oncology, 2008, 111, 111-119.	0.6	47
293	Proteomic study of the impact of the JAK2 V617F mutation on the phenotype of essential thrombocythemia. Experimental Hematology, 2008, 36, 1642-1647.	0.2	5
294	Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep. International Journal for Parasitology, 2008, 38, 123-136.	1.3	35
295	Applications of SELDI-MS technology in oncology. Journal of Cellular and Molecular Medicine, 2008, 12, 1535-1547.	1.6	50
296	Applications of mass spectrometry in oncology. , 2008, , 379-406.		0
297	Statistical Application and Challenges in Global Gel-Free Proteomic Analysis by Mass Spectrometry. Critical Reviews in Biotechnology, 2008, 28, 297-307.	5.1	19
299	Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncology, 2008, 4, 271-287.	1.1	26
300	Molecular Biomethods Handbook. Springer Protocols, 2008, , .	0.1	13
301	Fine-Needle Aspiration of Thyroid Nodules: Proteomic Analysis To Identify Cancer Biomarkers. Journal of Proteome Research, 2008, 7, 4079-4088.	1.8	99
302	Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Letters, 2008, 263, 280-290.	3.2	79
303	Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clinica Chimica Acta, 2008, 398, 48-52.	0.5	28
304	Surface enhanced laser desorption/ionization (SELDI): tecnología proteómica y su aplicación en oncología. Medicina Clínica, 2008, 131, 312-317.	0.3	2

#	ARTICLE	IF	CITATIONS
305	Glycoproteomic Analyses of Ovarian Cancer Cell Lines and Sera from Ovarian Cancer Patients Show Distinct Glycosylation Changes in Individual Proteins. <i>Journal of Proteome Research</i> , 2008, 7, 3776-3788.	1.8	72
306	Proteomics for biomarker discovery in malignant melanoma. <i>Expert Review of Dermatology</i> , 2008, 3, 209-220.	0.3	6
307	Biomarker rediscovery in diagnostics. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1391-1400.	1.6	9
308	Biomarkers in oncology research and treatment: early detection research network: a collaborative approach. <i>Biomarkers in Medicine</i> , 2008, 2, 181-195.	0.6	7
309	Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation. <i>Current Proteomics</i> , 2008, 5, 224-252.	0.1	11
310	Analysis of human plasma proteins: a focus on sample collection and separation using free-flow electrophoresis. <i>Expert Review of Proteomics</i> , 2008, 5, 571-587.	1.3	33
311	Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform. <i>Clinical Chemistry</i> , 2008, 54, 3-5.	1.5	29
312	Early detection of ovarian cancer. <i>Biomarkers in Medicine</i> , 2008, 2, 291-303.	0.6	74
313	A Proteomic Approach for the Diagnosis of "Oketsu"™ (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2008, 5, 463-474.	0.5	52
314	Mass spectrometry is only one piece of the puzzle in clinical proteomics. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2008, 7, 74-83.	3.8	24
315	Proteomic Contributions to Personalized Cancer Care. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1780-1794.	2.5	89
317	Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1420-1433.	2.5	74
319	Biomarker Discovery in Ovarian Cancer. <i>Women's Health</i> , 2008, 4, 27-40.	0.7	17
320	Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. <i>Expert Review of Proteomics</i> , 2008, 5, 551-560.	1.3	12
321	Biomarker Methods in Drug Discovery and Development. <i>Methods in Pharmacology and Toxicology</i> , 2008, , .	0.1	7
323	Ovarian Cancer Biomarkers: Current Options and Future Promise. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 795-802.	2.3	57
324	Computational & Statistical Methodologies to Identify Biomarkers in Cancer. <i>Current Cancer Therapy Reviews</i> , 2008, 4, 157-160.	0.2	0
325	Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2008, 3, 840-850.	0.5	26

#	ARTICLE	IF	CITATIONS
326	Discovery and application of protein biomarkers for ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 9-13.	0.9	39
327	Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2008, 6, 272-294.	0.2	3
329	<i>Clinical Proteomics and Molecular Pathology</i> . , 2009, , 165-183.		2
330	Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. <i>Oncology Reports</i> , 2009, 22, 205-13.	1.2	36
332	A simulation-approximation approach to sample size planning for high-dimensional classification studies. <i>Biostatistics</i> , 2009, 10, 424-435.	0.9	13
333	Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling. <i>Journal of Clinical Oncology</i> , 2009, 27, 2199-2208.	0.8	107
334	Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials. <i>Cancer Prevention Research</i> , 2009, 2, 525-530.	0.7	66
335	PROTEOMICS APPROACHES IN PRE-ECLAMPSIA RESEARCH. <i>Fetal and Maternal Medicine Review</i> , 2009, 20, 143-160.	0.3	0
336	Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 661-669.	2.5	107
337	Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 694-705.	1.4	31
338	SELDI-TOF-MS-based Serum Proteomic Screening in Combination with CT Scan Distinguishes Renal Cell Carcinoma from Benign Renal Tumors and Healthy Persons. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 225-230.	0.8	10
339	Biomedical Applications of Protein Microarrays. <i>Current Medicinal Chemistry</i> , 2009, 16, 2806-2815.	1.2	35
340	Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer. <i>Computer Journal</i> , 2009, 52, 326-333.	1.5	15
341	Early detection of cancer: immunoassays for plasma tumor markers. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 597-605.	1.6	54
342	Proteomic Analysis of Serum in Lung Cancer Induced by 3-Methylcholanthrene. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-12.	3.0	6
343	Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1328-1333.	0.5	68
344	Afamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1127-1133.	1.1	93
345	Application of proteomics in ovarian cancer: Which sample should be used?. <i>Gynecologic Oncology</i> , 2009, 115, 497-503.	0.6	13

#	ARTICLE	IF	CITATIONS
346	Validation of serum biomarkers for detection of early-stage ovarian cancer. American Journal of Obstetrics and Gynecology, 2009, 200, 639.e1-639.e5.	0.7	89
347	A review of current applications of mass spectrometry for neuroproteomics in epilepsy. Mass Spectrometry Reviews, 2010, 29, 197-246.	2.8	14
348	Derivatized graphitic nanofibres (GNF) as a new support material for mass spectrometric analysis of peptides and proteins. Amino Acids, 2009, 37, 341-348.	1.2	13
349	Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1240-1249.	1.2	73
350	Multifarious proteomic signatures and regional heterogeneity in glioblastomas. Journal of Neuro-Oncology, 2009, 94, 31-39.	1.4	23
351	Clinical proteomics in breast cancer: a review. Breast Cancer Research and Treatment, 2009, 116, 17-29.	1.1	78
352	Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery. Clinical Proteomics, 2009, 5, 148-155.	1.1	2
353	Discovery of metastasis-associated biomarkers in ovarian cancer using SELDI-TOF: An in vitro and clinical study. Clinical Oncology and Cancer Research, 2009, 6, 317-321.	0.1	2
354	Breast cancer-specific serum peptide profiles. Science Bulletin, 2009, 54, 421-429.	4.3	2
355	A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Proteomics, 2009, 9, 1044-1056.	1.3	28
356	Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles – initial evaluation using low molecular weight serum peaks. Proteomics, 2009, 9, 492-498.	1.3	20
357	Proteomic profiling of tumor cells after induction of telomere dysfunction. Proteomics, 2009, 9, 521-534.	1.3	2
358	Some statistics in bioinformatics: The fifth Armitage Lecture. Statistics in Medicine, 2009, 28, 2833-2856.	0.8	2
359	Mass spectrometry in clinical proteomics – from the present to the future. Proteomics - Clinical Applications, 2009, 3, 6-17.	0.8	71
360	Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics - Clinical Applications, 2009, 3, 853-861.	0.8	49
361	Identification of melanoma-specific serological markers using proteomic analyses. Proteomics - Clinical Applications, 2009, 3, 552-562.	0.8	3
362	Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. European Journal of Cancer Care, 2009, 18, 625-635.	0.7	38
363	Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstetrica Et Gynecologica Scandinavica, 2009, 88, 18-26.	1.3	52

#	ARTICLE	IF	CITATIONS
364	Platelets actively sequester angiogenesis regulators. <i>Blood</i> , 2009, 113, 2835-2842.	0.6	302
365	Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. <i>Cancer Letters</i> , 2009, 279, 163-170.	3.2	28
366	Proteomic identification and profiling of canine lymphoma patients*. <i>Veterinary and Comparative Oncology</i> , 2009, 7, 92-105.	0.8	15
367	Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 666-84.	1.4	34
368	Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2009, 8, 142-148.	1.8	44
369	Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 126.	3.5	21
371	Clinical Application of Proteomics in Ovarian Cancer Prevention and Treatment. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 297-311.	1.6	17
372	Mass Spectrometry-based Proteomic Profiling of Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 159-170.	3.5	44
373	Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis. <i>Bioanalysis</i> , 2009, 1, 847-855.	0.6	17
375	Identification of two new serum protein profiles for renal cell carcinoma. <i>Oncology Reports</i> , 2009, , .	1.2	0
376	Proteomic Analysis of HCV Cirrhosis and HCV-Induced HCC: Identifying Biomarkers for Monitoring HCV-Cirrhotic Patients Awaiting Liver Transplantation. <i>Transplantation</i> , 2009, 87, 143-152.	0.5	29
377	A cube framework for incorporating inter-gene information into biological data mining. <i>International Journal of Data Mining and Bioinformatics</i> , 2009, 3, 3.	0.1	4
379	A Proteomics Panel for Predicting Optimal Primary Cytoreduction in Stage III/IV Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1535-1538.	1.2	5
380	Prevalence of Antitumor Antibodies in Laying Hen Model of Human Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 500-507.	1.2	23
381	Current clinical use of biomarkers for epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 492-497.	1.1	41
382	Confirmation of the biological significance of transthyretin as a biomarker for cutaneous T-cell lymphoma by its protein interaction partners. <i>Molecular Medicine Reports</i> , 2011, 4, 157-61.	1.1	3
383	Strategy for Degradomic-Peptidomic Analysis of Human Blood Plasma. <i>Journal of Proteome Research</i> , 2010, 9, 2339-2346.	1.8	43
384	Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 737-749.	1.9	25

#	ARTICLE	IF	CITATIONS
385	Identification of potential serum markers for endometrial cancer using protein expression profiling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 475-481.	1.2	18
386	Will Cancer Proteomics Suffer from Premature Death?. <i>Clinical Proteomics</i> , 2010, 6, 1-3.	1.1	7
387	Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. <i>Clinical Proteomics</i> , 2010, 6, 115-127.	1.1	11
388	In-silico prediction of blood-secretory human proteins using a ranking algorithm. <i>BMC Bioinformatics</i> , 2010, 11, 250.	1.2	16
389	Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. <i>Electrophoresis</i> , 2010, 31, 599-610.	1.3	58
390	A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. <i>Electrophoresis</i> , 2010, 31, 1721-1730.	1.3	17
391	Cancer-specific MALDI-TOF profiles of blood serum and plasma: Biological meaning and perspectives. <i>Journal of Proteomics</i> , 2010, 73, 537-551.	1.2	59
392	Reduced plasma APOA1 level is associated with Gastric Tumor Growth in MKN45 mouse xenograft model. <i>Journal of Proteomics</i> , 2010, 73, 1632-1640.	1.2	51
393	Murine fecal proteomics: A model system for the detection of potential biomarkers for colorectal cancer. <i>Journal of Chromatography A</i> , 2010, 1217, 3330-3340.	1.8	34
394	The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients. <i>AIDS Research and Therapy</i> , 2010, 7, 21.	0.7	9
395	Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 304-314.	0.8	22
396	Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. <i>Proteomics - Clinical Applications</i> , 2010, 4, 940-952.	0.8	26
397	The absolute quantification of eight inter- $\alpha$ -trypsin inhibitor heavy chain 4 (ITIH <sub>4</sub> )-derived peptides in serum from breast cancer patients. <i>Proteomics - Clinical Applications</i> , 2010, 4, 931-939.	0.8	33
398	Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. <i>Proteomics</i> , 2010, 10, 3525-3532.	1.3	19
399	A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010, 10, 3388-3392.	1.3	32
400	Biochips that sequentially capture and focus antigens for immunoaffinity MALDI-TOF MS: A new tool for biomarker verification. <i>Proteomics</i> , 2010, 10, 3922-3927.	1.3	17
401	Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH <sub>4</sub> -derived putative biomarker peptides in clinical serum samples. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 1842-1850.	0.7	18
402	Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. <i>British Journal of Cancer</i> , 2010, 103, 223-231.	2.9	20

#	ARTICLE	IF	CITATIONS
403	Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. <i>British Journal of Cancer</i> , 2010, 103, 232-238.	2.9	23
404	Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). <i>Leukemia</i> , 2010, 24, 1875-1884.	3.3	14
405	Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 371-378.	12.8	140
406	Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16. <i>Disease Markers</i> , 2010, 28, 385-394.	0.6	24
407	Serum Biomarkers for Early Detection of Gynecologic Cancers. <i>Cancers</i> , 2010, 2, 1312-1327.	1.7	36
408	A Recipe for Proteomics Diagnostic Test Development: The OVA1 Test, from Biomarker Discovery to FDA Clearance. <i>Clinical Chemistry</i> , 2010, 56, 327-329.	1.5	126
409	Rapid Multiplexed Genotyping for Hereditary Thrombophilia by SELDI-TOF Mass Spectrometry. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 54-61.	2.1	3
410	10 Years of SELDI: What Have we Learnt?. <i>Current Proteomics</i> , 2010, 7, 15-25.	0.1	6
411	Mass Spectrometry-Based Protein Biomarker Discovery: Solving the Remaining Challenges to Reach the Promise of Clinical Benefit. <i>Clinical Chemistry</i> , 2010, 56, 1641-1642.	1.5	27
412	Tumor markers for early detection of ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 787-798.	1.5	25
413	Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 26-38.	3.0	182
414	Apolipoprotein A1 and Transferrin as Biomarkers in Ovarian Cancer Diagnostics. <i>Acta Chirurgica Latviensis</i> , 2010, 10, 16-20.	0.2	6
415	The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2995-2999.	1.1	169
417	Tumor Markers: The Potential of Omics Approach. <i>Current Molecular Medicine</i> , 2010, 10, 249-257.	0.6	29
419	Proteomic Assays for the Detection of Urothelial Cancer. <i>Methods in Molecular Biology</i> , 2010, 641, 303-323.	0.4	17
420	Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. <i>Oncology Reports</i> , 2010, 24, 57-64.	1.2	20
421	The Urinary Proteome. <i>Methods in Molecular Biology</i> , 2010, , .	0.4	1
422	Ovarian cancer biomarkers for molecular biosensors and translational medicine. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 1069-1083.	1.5	88

#	ARTICLE	IF	CITATIONS
423	Proteomic analysis of serum yields six candidate proteins that are differentially regulated in a subset of women with endometriosis. <i>Fertility and Sterility</i> , 2010, 93, 2137-2144.	0.5	50
424	An Approach to Multiplexing an Immunosorbent Assay with Antibody-oligonucleotide Conjugates. <i>Bioconjugate Chemistry</i> , 2010, 21, 2190-2196.	1.8	18
425	An Omics Perspective on Cancer Research. , 2010, , .		20
426	Translational Medicine: Application of Omics for Drug Target Discovery and Validation. , 2010, , 235-247.		4
427	Culture of human cells and synthesis of extracellular matrix on materials compatible with direct analysis by mass spectrometry. <i>Analyst, The</i> , 2010, 135, 503.	1.7	11
428	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2159-2166.	0.8	246
429	Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. <i>Rheumatology</i> , 2010, 49, 671-682.	0.9	110
430	Molecular Signatures of Ovarian Cancer. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 13-22.	1.6	11
431	Proteomic profiling of peritoneal rinse fluid sediment separates patients with ovarian cancer from women admitted for cesarean section. A pilot study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 470-477.	0.6	1
432	Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. <i>Archives of Physiology and Biochemistry</i> , 2010, 116, 197-207.	1.0	3
433	Clinical Application of Proteomics in Breast Cancer: State of the Art and Perspectives. <i>Medical Principles and Practice</i> , 2011, 20, 4-18.	1.1	21
434	A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. <i>Cancer Prevention Research</i> , 2011, 4, 375-383.	0.7	160
435	The Neuroproteomics of Schizophrenia. <i>Biological Psychiatry</i> , 2011, 69, 163-172.	0.7	122
436	Human urine proteomics: building a list of human urine cancer biomarkers. <i>Expert Review of Proteomics</i> , 2011, 8, 347-360.	1.3	21
437	Identification of Novel Diagnostic Biomarkers for Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1633-1643.	2.5	91
438	Applying Random Forests To Identify Biomarker Panels in Serum 2D-DIGE Data for the Detection and Staging of Prostate Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 1361-1373.	1.8	64
439	Evaluation of endometrial biomarkers for semi-invasive diagnosis of endometriosis. <i>Fertility and Sterility</i> , 2011, 95, 1338-1343.e3.	0.5	41
440	An overview of biomarkers for the ovarian cancer diagnosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 158, 119-123.	0.5	69



#	ARTICLE	IF	CITATIONS
441	Regulatory perspective on translating proteomic biomarkers to clinical diagnostics. <i>Journal of Proteomics</i> , 2011, 74, 2682-2690.	1.2	24
442	Acute Phase Proteins as Cancer Biomarkers. , 2011, , .		2
443	Evaluation of Proteomics-Identified CCL18 and CXCL1 as Circulating Tumor Markers for Differential Diagnosis between Ovarian Carcinomas and Benign Pelvic Masses. <i>International Journal of Biological Markers</i> , 2011, 26, 262-273.	0.7	40
444	Serum Proteomic Profiling Reveals Potential Biomarkers for Cutaneous Malignant Melanoma. <i>International Journal of Biological Markers</i> , 2011, 26, 82-87.	0.7	14
445	Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. <i>PLoS ONE</i> , 2011, 6, e14540.	1.1	43
446	Searching for a system: The quest for ovarian cancer biomarkers. <i>Cancer Biomarkers</i> , 2011, 8, 223-230.	0.8	8
447	Relationship between Clinicopathologic Variables and Serum and Tissue Levels of Dickkopf-1 in Patients with Rectal Cancer. <i>Journal of Investigative Medicine</i> , 2011, 59, 947-950.	0.7	11
448	Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors. <i>Obstetrics and Gynecology</i> , 2011, 117, 1289-1297.	1.2	202
449	Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. <i>Oncology Reports</i> , 2011, 27, 318-24.	1.2	35
450	Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. <i>Cancer Science</i> , 2011, 102, 630-638.	1.7	58
451	Dietary whey hydrolysate with exercise alters the plasma protein profile: A comprehensive protein analysis. <i>Nutrition</i> , 2011, 27, 687-692.	1.1	11
452	Serum Proteome Analysis for Profiling Protein Markers Associated with Lymph Node Metastasis in Colorectal Carcinoma. <i>Journal of Comparative Pathology</i> , 2011, 144, 187-194.	0.1	18
453	Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011, 64, 197-206.	0.3	18
454	Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. <i>Gynecologic Oncology</i> , 2011, 120, 152-157.	0.6	62
455	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 548-553.	0.6	73
456	A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 308-313.	0.6	27
457	Serum cancer biomarker discovery through analysis of gene expression data sets across multiple tumor and normal tissues. <i>Journal of Biomedical Informatics</i> , 2011, 44, 1076-1085.	2.5	7
458	Biomarker discovery for ovine paratuberculosis (Johne's disease) by proteomic serum profiling. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2011, 34, 315-326.	0.7	22

#	ARTICLE	IF	CITATIONS
459	In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. <i>Journal of Proteome Research</i> , 2011, 10, 2286-2299.	1.8	72
460	Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. <i>Cancer Causes and Control</i> , 2011, 22, 1011-1019.	0.8	63
461	Apolipoprotein A1 $\Delta$ 75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. <i>Molecular Biology Reports</i> , 2011, 38, 1637-1643.	1.0	28
462	Breast cancer proteomics: a review for clinicians. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 915-925.	1.2	43
463	Efficacy of calcium supplementation for human bone health by mass spectrometry profiling and cathepsin K measurement in plasma samples. <i>Journal of Bone and Mineral Metabolism</i> , 2011, 29, 552-560.	1.3	3
464	Identification of haptoglobin and apolipoprotein A-I as biomarkers for high altitude pulmonary edema. <i>Functional and Integrative Genomics</i> , 2011, 11, 407-417.	1.4	36
465	Novel multifunctional chitosan-GMA-IDA-Cu(II) nanospheres for high dynamic range characterization of the human plasma proteome. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 747-756.	1.9	8
466	Cancer: A proteomic disease. <i>Science China Life Sciences</i> , 2011, 54, 403-408.	2.3	19
467	Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies. <i>Proteome Science</i> , 2011, 9, 36.	0.7	8
468	Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. <i>Proteome Science</i> , 2011, 9, 64.	0.7	18
469	Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. <i>Journal of Ovarian Research</i> , 2011, 4, 18.	1.3	46
470	An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring. <i>Proteomics - Clinical Applications</i> , 2011, 5, 532-541.	0.8	19
471	Proteome and cytokine serum profiling to diagnose a mycosis fungoides. <i>Proteomics - Clinical Applications</i> , 2011, 5, 432-439.	0.8	9
472	The first decade of MALDI protein profiling: A lesson in translational biomarker research. <i>Journal of Proteomics</i> , 2011, 74, 765-773.	1.2	49
473	Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 1537-1542.	2.8	19
474	Building Biomarker Combinations for Korean Ovarian Cancer Screening Using Statistics and Machine Learning. <i>Applied Mechanics and Materials</i> , 2011, 145, 229-233.	0.2	1
475	Reproducibility of SELDI Spectra across Time and Laboratories. <i>Cancer Informatics</i> , 2011, 10, CIN.S6438.	0.9	14
476	Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses. <i>Journal of the Turkish German Gynecology Association</i> , 2011, 12, 214-219.	0.2	7

#	ARTICLE	IF	CITATIONS
477	Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. <i>Cancer Prevention Research</i> , 2011, 4, 365-374.	0.7	256
478	Identification of Cervical Cancer Proteins Associated With Treatment With Paclitaxel and Cisplatin in Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1452-1457.	1.2	12
479	Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. <i>Obstetrics and Gynecology</i> , 2011, 117, 1298-1306.	1.2	72
480	An empirical assessment of validation practices for molecular classifiers. <i>Briefings in Bioinformatics</i> , 2011, 12, 189-202.	3.2	85
481	AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. <i>Experimental and Molecular Medicine</i> , 2011, 43, 91.	3.2	76
482	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13926-13948.	1.8	56
483	Potential Biomarkers in the Sera of Breast Cancer Patients from Bahawalpur, Pakistan. <i>Biomarkers in Cancer</i> , 2012, 4, BIC.S10502.	3.6	12
484	MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment. <i>International Journal of Proteomics</i> , 2012, 2012, 1-10.	2.0	16
485	Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. <i>Journal of Biomedical Optics</i> , 2012, 17, 081412.	1.4	18
486	Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and fibroblasts using contactless dielectrophoresis. <i>Biomicrofluidics</i> , 2012, 6, 024104.	1.2	52
487	Metabolic Syndrome Components and Risk Factors for Pancreatic Adenocarcinoma: A Case-Control Study in China. <i>Digestion</i> , 2012, 86, 294-301.	1.2	23
488	Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1902-1912.	1.1	89
489	Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. <i>Oncology Reports</i> , 2012, 28, 585-591.	1.2	16
490	2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. <i>Journal of Proteomics</i> , 2012, 77, 40-58.	1.2	26
491	Role of proteomics in biomarker discovery and psychiatric disorders: current status, potentials, limitations and future challenges. <i>Expert Review of Proteomics</i> , 2012, 9, 249-265.	1.3	10
492	Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. <i>Expert Review of Proteomics</i> , 2012, 9, 599-614.	1.3	26
493	Recent progress in quantitative glycoproteomics. <i>Glycoconjugate Journal</i> , 2012, 29, 249-258.	1.4	55
495	Multiplex detection platform for tumor markers and glucose in serum based on a microfluidic microparticle array. <i>Analytica Chimica Acta</i> , 2012, 751, 146-154.	2.6	30

#	ARTICLE	IF	CITATIONS
496	Resolving Low-Expression Cell Surface Antigens by Time-Gated Orthogonal Scanning Automated Microscopy. <i>Analytical Chemistry</i> , 2012, 84, 9674-9678.	3.2	16
497	Protein biomarkers of ovarian cancer: the forest and the trees. <i>Future Oncology</i> , 2012, 8, 55-71.	1.1	74
498	Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer. <i>Medical Hypotheses</i> , 2012, 78, 407-409.	0.8	3
499	Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. <i>Journal of Proteomics</i> , 2012, 75, 3270-3290.	1.2	23
500	Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. <i>Proteome Science</i> , 2012, 10, 31.	0.7	12
501	A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. <i>Proteome Science</i> , 2012, 10, 45.	0.7	19
502	Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. <i>Journal of Translational Medicine</i> , 2012, 10, 45.	1.8	18
503	Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. <i>Clinical Proteomics</i> , 2012, 9, 10.	1.1	23
504	Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. <i>Clinical Proteomics</i> , 2012, 9, 14.	1.1	23
505	Serum protein profiles as potential biomarkers for infectious disease status in pigs. <i>BMC Veterinary Research</i> , 2012, 8, 32.	0.7	18
506	Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics. <i>Science Translational Medicine</i> , 2012, 4, 142ra94.	5.8	236
507	From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. <i>Biomarkers in Medicine</i> , 2012, 6, 613-625.	0.6	24
508	Inflammatory, immune and lipid transportation proteins are differentially expressed in spontaneous and proximal deep vein thrombosis patients. <i>Thrombosis Research</i> , 2012, 130, e246-e250.	0.8	5
509	Identification and Confirmation of Differentially Expressed Fucosylated Glycoproteins in the Serum of Ovarian Cancer Patients Using a Lectin Array and LC-MS/MS. <i>Journal of Proteome Research</i> , 2012, 11, 4541-4552.	1.8	102
510	Changes of Transthyretin and Clusterin after Androgen Ablation Therapy and Correlation with Prostate Cancer Malignancy. <i>Translational Oncology</i> , 2012, 5, 124-IN9.	1.7	11
511	Proteomics: methodologies and applications to the study of human diseases. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2012, 58, 366-375.	0.1	8
512	A Xenograft Mouse Model Coupled with In-depth Plasma Proteome Analysis Facilitates Identification of Novel Serum Biomarkers for Human Ovarian Cancer. <i>Journal of Proteome Research</i> , 2012, 11, 678-691.	1.8	51
513	Development of Multiplexed Bead-Based Immunoassays for the Detection of Early Stage Ovarian Cancer Using a Combination of Serum Biomarkers. <i>PLoS ONE</i> , 2012, 7, e44960.	1.1	48

#	ARTICLE	IF	CITATIONS
514	Alterations in Cerebrospinal Fluid Proteins in a Presymptomatic Primary Glioma Model. PLoS ONE, 2012, 7, e49724.	1.1	16
515	The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers. Proteomics, 2012, 12, 1883-1891.	1.3	26
516	"The quest for biomarkers": Are we on the right technical track?. Proteomics - Clinical Applications, 2012, 6, 22-41.	0.8	24
517	The current status of clinical proteomics and the use of MRM and MRM <sup>3</sup> for biomarker validation. Expert Review of Molecular Diagnostics, 2012, 12, 333-342.	1.5	44
518	Parallel factor analysis of ovarian autofluorescence as a cancer diagnostic. Lasers in Surgery and Medicine, 2012, 44, 282-295.	1.1	14
519	Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses. Electrophoresis, 2012, 33, 1855-1862.	1.3	32
520	Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads. International Journal of Clinical Oncology, 2012, 17, 89-95.	1.0	16
521	Proteomic analyses of human plasma: Venus versus Mars. Transfusion, 2012, 52, 417-424.	0.8	48
522	Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. Journal of Proteomics, 2012, 75, 2758-2772.	1.2	16
523	Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer, 2012, 118, 91-100.	2.0	77
524	Advances in MALDI Mass Spectrometry in Clinical Diagnostic Applications. Topics in Current Chemistry, 2013, 336, 139-175.	4.0	33
525	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium. BMC Cancer, 2013, 13, 178.	1.1	29
526	Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. Expert Opinion on Medical Diagnostics, 2013, 7, 37-51.	1.6	154
527	Immobilized metal affinity chromatography and human serum proteomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 934, 26-33.	1.2	38
528	Human Epididymis Protein 4 in Cancer Diagnostics. Advances in Clinical Chemistry, 2013, 59, 1-21.	1.8	25
529	Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1757-1770.	1.2	33
530	Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. Journal of Proteomics, 2013, 89, 165-178.	1.2	69
531	Biomarker Testing for Ovarian Cancer: Clinical Utility of Multiplex Assays. Molecular Diagnosis and Therapy, 2013, 17, 139-146.	1.6	78

#	ARTICLE	IF	CITATIONS
532	Apolipoprotein Concentrations Are Elevated in Malignant Ovarian Cyst Fluids Suggesting That Lipoprotein Metabolism Is Dysregulated in Epithelial Ovarian Cancer. <i>Cancer Investigation</i> , 2013, 31, 258-272.	0.6	14
533	Tailoring of a TiO <sub>2</sub> nanotube array-integrated portable microdevice for efficient on-chip enrichment and isotope labeling of serum phosphopeptides. <i>Lab on A Chip</i> , 2013, 13, 3853.	3.1	15
534	Detection and monitoring of ovarian cancer. <i>Clinica Chimica Acta</i> , 2013, 415, 341-345.	0.5	89
535	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	0.6	22
536	Chromosome 18 Transcriptome Profiling and Targeted Proteome Mapping in Depleted Plasma, Liver Tissue and HepG2 Cells. <i>Journal of Proteome Research</i> , 2013, 12, 123-134.	1.8	59
537	Novel biospectroscopy sensor technologies towards environmental health monitoring in urban environments. <i>Environmental Pollution</i> , 2013, 183, 46-53.	3.7	14
539	High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques. <i>Medical Oncology</i> , 2013, 30, 420.	1.2	27
540	Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. <i>International Journal of Molecular Sciences</i> , 2013, 14, 640-673.	1.8	20
541	Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells. <i>International Journal of Cancer</i> , 2013, 133, 1143-1152.	2.3	31
542	Altered Expression of Sialylated Glycoproteins in Ovarian Cancer Sera Using Lectin-based ELISA Assay and Quantitative Glycoproteomics Analysis. <i>Journal of Proteome Research</i> , 2013, 12, 3342-3352.	1.8	59
543	Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. <i>Proteomics</i> , 2013, 13, 2361-2374.	1.3	61
544	Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. <i>Mass Spectrometry Reviews</i> , 2013, 32, 267-311.	2.8	15
545	Alternatives to risk-reducing surgery for ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii47-viii53.	0.6	15
546	Amplification of interference color by using liquid crystal for protein detection. <i>Applied Physics Letters</i> , 2013, 103, .	1.5	4
547	Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. <i>Hepatitis Monthly</i> , 2013, 13, e8351.	0.1	28
548	Comparative Proteomics of Sera From HCC Patients With Different Origins. <i>Hepatitis Monthly</i> , 2013, 14, e13103.	0.1	16
549	Ovarian Cyst Fluids Are a Cache of Tumor Biomarkers That Include Calgranulin A and Calgranulin B Isoforms. <i>Cancer Investigation</i> , 2013, 31, 433-453.	0.6	2
550	Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8271-8290.	1.8	32

#	ARTICLE	IF	CITATIONS
551	Nature of Light. Reproductive Sciences, 2013, 20, 500-513.	1.1	1
552	Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors. International Journal of Proteomics, 2013, 2013, 1-15.	2.0	33
553	On best practices: The Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics-based diagnostic and predictive tests. Proteomics - Clinical Applications, 2013, 7, 748-755.	0.8	6
554	Identification of serum CCL15 in hepatocellular carcinoma. British Journal of Cancer, 2013, 108, 99-106.	2.9	30
555	Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy. Oncology Reports, 2013, 29, 355-361.	1.2	2
556	Identification of Potential Prognostic Markers for Knee Osteoarthritis by Serum Proteomic Analysis. Biomarker Insights, 2013, 8, BMI.S11966.	1.0	22
557	An Insight into the Changes in Human Plasma Proteome on Adaptation to Hypobaric Hypoxia. PLoS ONE, 2013, 8, e67548.	1.1	51
558	Serum Proteome Analysis for Profiling Predictive Protein Markers Associated with the Severity of Skin Lesions Induced by Ionizing Radiation. Proteomes, 2013, 1, 40-69.	1.7	16
559	The Genetics of Ovarian Cancer. , 2013, , .		0
560	Biochemical markers for screening of ovarian cancer. Przegląd Menopauzalny, 2013, 5, 442-445.	0.6	0
561	Label-Free LC-MSe in Tissue and Serum Reveals Protein Networks Underlying Differences between Benign and Malignant Serous Ovarian Tumors. PLoS ONE, 2014, 9, e108046.	1.1	19
562	Pancreatic and ovarian cancer biomarkers. , 2014, , 759-770.		1
563	Proteomic changes in the cortex membrane fraction of genetic absence epilepsy rats from Strasbourg. Journal of Integrative Neuroscience, 2014, 13, 633-644.	0.8	3
564	Ovarian Cancer Biomarkers. Advances in Clinical Chemistry, 2014, , 25-77.	1.8	20
565	Proteomics Analysis for Finding Serum Markers of Ovarian Cancer. BioMed Research International, 2014, 2014, 1-9.	0.9	40
566	Proteomic cancer biomarkers from discovery to approval: it's worth the effort. Expert Review of Proteomics, 2014, 11, 135-136.	1.3	42
567	Effective peak alignment for mass spectrometry data analysis using two-phase clustering approach. International Journal of Data Mining and Bioinformatics, 2014, 9, 52.	0.1	5
568	The role of proteomics in understanding biological mechanisms of sepsis. Proteomics - Clinical Applications, 2014, 8, 35-52.	0.8	40

#	ARTICLE	IF	CITATIONS
569	Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R63.	2.2	90
570	APOA1 mRNA Expression in Ovarian Serous Carcinoma Effusions Is a Marker of Longer Survival. <i>American Journal of Clinical Pathology</i> , 2014, 142, 51-57.	0.4	28
571	A bibliometric analysis of research on proteomics in Science Citation Index Expanded. <i>Scientometrics</i> , 2014, 98, 1473-1490.	1.6	73
572	Advances in Diagnosis and Management of Ovarian Cancer. , 2014, , .		3
573	Profiling proteoforms: promising follow-up of proteomics for biomarker discovery. <i>Expert Review of Proteomics</i> , 2014, 11, 121-129.	1.3	44
574	Towards an Animal Model of Ovarian Cancer: Cataloging Chicken Blood Proteins Using Combinatorial Peptide Ligand Libraries Coupled with Shotgun Proteomic Analysis for Translational Research. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 280-297.	1.0	7
575	Chemical Diagnostics. <i>Topics in Current Chemistry</i> , 2014, , .	4.0	2
576	Fiber based enzyme-linked immunosorbent assay for C-reactive protein. <i>Sensors and Actuators B: Chemical</i> , 2014, 205, 50-60.	4.0	28
577	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014, 8, 982-993.	0.8	41
578	Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. <i>Medical Oncology</i> , 2014, 31, 80.	1.2	36
579	Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. <i>Tumor Biology</i> , 2014, 35, 9751-9757.	0.8	7
580	Plasmonic micro-beads for fluorescence enhanced, multiplexed protein detection with flow cytometry. <i>Chemical Science</i> , 2014, 5, 4070-4075.	3.7	38
581	Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Clinical Biochemistry</i> , 2014, 47, 1257-1261.	0.8	20
583	Site-Specific Glycan Microheterogeneity of Inter-Alpha-Trypsin Inhibitor Heavy Chain H4. <i>Journal of Proteome Research</i> , 2014, 13, 3314-3329.	1.8	35
584	In 2014, can we do better than CA125 in the early detection of ovarian cancer?. <i>World Journal of Biological Chemistry</i> , 2014, 5, 286.	1.7	58
585	Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer. <i>Oncology Letters</i> , 2014, 8, 566-574.	0.8	18
586	Alterations in the serum proteome profile during the development of ovarian cancer. <i>International Journal of Oncology</i> , 2014, 45, 2495-2501.	1.4	7
587	CSF protein dynamic driver network: At the crossroads of brain tumorigenesis. , 2014, , .		0



#	ARTICLE	IF	CITATIONS
588	Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma. Chinese Medical Journal, 2015, 128, 1108-1113.	0.9	24
589	Validation of LRG1 as a Potential Biomarker for Detection of Epithelial Ovarian Cancer by a Blinded Study. PLoS ONE, 2015, 10, e0121112.	1.1	27
590	Apolipoprotein A-I and Cancer. Frontiers in Pharmacology, 2015, 6, 265.	1.6	71
591	Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, $\beta$ -2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis. Biosensors and Bioelectronics, 2015, 73, 146-152.	5.3	63
592	High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system. Biosensors and Bioelectronics, 2015, 73, 32-40.	5.3	34
593	Important options available "from start to finish" for translating proteomics results to clinical chemistry. Proteomics - Clinical Applications, 2015, 9, 235-252.	0.8	8
594	Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Medical Oncology, 2015, 32, 407.	1.2	26
595	Usefulness of Diagnostic Indices Comprising Clinical, Sonographic, and Biomarker Data for Discriminating Benign From Malignant Ovarian Masses. Journal of Ultrasound in Medicine, 2015, 34, 207-217.	0.8	20
596	Reorganization of low-molecular-weight fraction of plasma proteins in the annual cycle of cyprinidae. Biochemistry (Moscow), 2015, 80, 208-218.	0.7	9
597	OMICS for Tumor Biomarker Research. Biomarkers in Disease, 2015, , 3-30.	0.0	3
598	Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal of the National Cancer Institute, 2015, 107, 322.	3.0	16
599	Identification of Epithelial Ovarian Tumor-Specific Aptamers. Nucleic Acid Therapeutics, 2015, 25, 162-172.	2.0	18
600	Giant magnetoresistive-based biosensing probe station system for multiplex protein assays. Biosensors and Bioelectronics, 2015, 70, 61-68.	5.3	68
601	Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer. Proteomics - Clinical Applications, 2015, 9, 586-596.	0.8	13
602	Proteomics of ovarian cancer: functional insights and clinical applications. Cancer and Metastasis Reviews, 2015, 34, 83-96.	2.7	55
603	Biomarkers identified from serum proteomic analysis for the differential diagnosis of systemic lupus erythematosus. Lupus, 2015, 24, 582-587.	0.8	22
604	Evaluation of haemoglobin in blister fluid as an indicator of paediatric burn wound depth. Burns, 2015, 41, 1114-1121.	1.1	7
605	Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods. Biotechnology Progress, 2015, 31, 832-839.	1.3	45

#	ARTICLE	IF	CITATIONS
606	Transformative Impact of Proteomics on Cardiovascular Health and Disease. <i>Circulation</i> , 2015, 132, 852-872.	1.6	140
607	Cerebrospinal fluid protein dynamic driver network: At the crossroads of brain tumorigenesis. <i>Methods</i> , 2015, 83, 36-43.	1.9	11
608	Unique expression of 35 KDa protein in serum and cystic fluid of women with malignant ovarian cysts substantiates its role in disease progression. <i>Asian Pacific Journal of Reproduction</i> , 2015, 4, 298-304.	0.2	2
609	The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 229-244.	0.8	130
610	Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes. <i>Journal of Proteome Research</i> , 2015, 14, 422-433.	1.8	26
611	Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. <i>Clinica Chimica Acta</i> , 2015, 438, 358-363.	0.5	28
612	Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. <i>Scientific Reports</i> , 2014, 4, 4116.	1.6	144
613	Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2016, 58, 23-33.	0.6	6
614	Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects. <i>Brazilian Archives of Biology and Technology</i> , 2016, 59, .	0.5	19
615	Identifying joint biomarker panel from multiple level dataset by an optimization model. <i>Biomarkers in Medicine</i> , 2016, 10, 567-575.	0.6	1
616	Terahertz molecular resonance of cancer DNA. <i>Scientific Reports</i> , 2016, 6, 37103.	1.6	136
617	Biosensor surface attachment of the ovarian cancer biomarker HSP10 via His-tag modification. <i>Sensing and Bio-Sensing Research</i> , 2016, 11, 107-112.	2.2	6
618	Highly dispersed magnetic molecularly imprinted nanoparticles with well-defined thin film for the selective extraction of glycoprotein. <i>Journal of Materials Chemistry B</i> , 2016, 4, 2620-2627.	2.9	40
619	Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics. <i>Expert Review of Proteomics</i> , 2016, 13, 593-607.	1.3	12
620	Advances in mass spectrometry-based clinical biomarker discovery. <i>Clinical Proteomics</i> , 2016, 13, 1.	1.1	218
621	Highly Sensitive Protein Detection Based on Smart Hybrid Nanocomposite-Controlled Switch of DNA Polymerase Activity. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 28202-28207.	4.0	16
622	Basics of Mass Spectrometry and Its Applications in Biomarker Discovery. , 2016, , 41-63.		0
623	Biomarkers of inflammation and innate immunity in atrophic nonunion fracture. <i>Journal of Translational Medicine</i> , 2016, 14, 258.	1.8	15

#	ARTICLE	IF	CITATIONS
624	Clinical proteomics in cancer: Where we are. <i>Cancer Letters</i> , 2016, 382, 231-239.	3.2	27
625	The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. <i>Biomedical Reports</i> , 2016, 5, 41-44.	0.9	65
626	High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 516.	1.1	29
627	Experimental and theoretical investigation of the precise transduction mechanism in giant magnetoresistive biosensors. <i>Scientific Reports</i> , 2016, 6, 18692.	1.6	21
628	Scope and limitations of MALDI-TOF MS blood serum peptide profiling in cancer diagnostics. <i>Russian Journal of Bioorganic Chemistry</i> , 2016, 42, 497-505.	0.3	2
629	A Bayesian algorithm for detecting differentially expressed proteins and its application in breast cancer research. <i>Scientific Reports</i> , 2016, 6, 30159.	1.6	4
630	Establishment and characterization of a highly immunogenic human renal carcinoma cell line. <i>International Journal of Oncology</i> , 2016, 49, 457-470.	1.4	3
631	Searching urinary tumor-associated proteins for bladder transitional cell carcinoma in southwestern Taiwan using gel-based proteomics. <i>Urological Science</i> , 2016, 27, 250-257.	0.2	0
632	Clinical implications of recent advances in proteogenomics. <i>Expert Review of Proteomics</i> , 2016, 13, 185-199.	1.3	12
633	Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 82.e1-82.e11.	0.7	95
634	Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury. <i>Experimental Biology and Medicine</i> , 2016, 241, 1186-1194.	1.1	10
635	Protein species as diagnostic markers. <i>Journal of Proteomics</i> , 2016, 134, 5-18.	1.2	24
636	Mass spectrometric based approaches in urine metabolomics and biomarker discovery. <i>Mass Spectrometry Reviews</i> , 2017, 36, 115-134.	2.8	230
637	From genome to proteome: Looking beyond DNA and RNA in chronic lymphocytic leukemia. <i>Journal of Proteomics</i> , 2017, 155, 73-84.	1.2	6
638	Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 199-204.	12.8	318
639	The PeptideAtlas of the Domestic Laying Hen. <i>Journal of Proteome Research</i> , 2017, 16, 1352-1363.	1.8	9
640	Ovarian Cancer Biomarkers in Circulation. , 2017, , 371-398.		0
641	Discovery of lung squamous carcinoma biomarkers by profiling the plasma peptide with LC/MS/MS. <i>Chinese Chemical Letters</i> , 2017, 28, 1093-1098.	4.8	6

#	ARTICLE	IF	CITATIONS
642	Electrohydrodynamicâ€induced SERS Immunoassay for Extensive Multiplexed Biomarker Sensing. Small, 2017, 13, 1602902.	5.2	79
643	Revisiting biomarker discovery by plasmaâ€proteomics. Molecular Systems Biology, 2017, 13, 942.	3.2	597
644	Mass spectrometry-based proteomics in cancer research. Expert Review of Proteomics, 2017, 14, 725-727.	1.3	20
645	An integrated microfluidic system for the isolation and detection of ovarian circulating tumor cells using cell selection and enrichment methods. Biomicrofluidics, 2017, 11, 034122.	1.2	22
646	An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. Clinical Proteomics, 2017, 14, 16.	1.1	14
648	Quantitative body fluid proteomics in medicine â€ A focus on minimal invasiveness. Journal of Proteomics, 2017, 153, 30-43.	1.2	62
650	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. ELife, 2017, 6, .	2.8	106
651	A multiplex platform for the identification of ovarian cancer biomarkers. Clinical Proteomics, 2017, 14, 34.	1.1	25
652	Prealbumin and Retinol Binding Protein as Screening Tools for Malnutrition. , 2017, , 1-21.		2
653	Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins. Cancer Genomics and Proteomics, 2017, 14, 35-52.	1.0	51
654	Molecular Signatures of Biomarkers in Cancer Development, Diagnosis, and its Prognostic Accuracy. Current Biomarkers, 2017, 6, .	0.3	4
655	The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA Journal, 2018, 9, 77-102.	3.3	184
656	Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125. Journal of Gynecology Obstetrics and Human Reproduction, 2018, 47, 227-230.	0.6	27
657	Hydrophilic probe in mesoporous pore for selective enrichment of endogenous glycopeptides in biological samples. Analytica Chimica Acta, 2018, 1024, 84-92.	2.6	46
658	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. Leukemia and Lymphoma, 2018, 59, 1016-1018.	0.6	0
659	Phosphatidylserine: A cancer cell targeting biomarker. Seminars in Cancer Biology, 2018, 52, 17-25.	4.3	128
660	ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(<sc>i</sc>) complexes. Analyst, The, 2018, 143, 6087-6094.	1.7	19
661	Development of a Novel Diagnostic Biomarker Set for Rheumatoid Arthritis Using a Proteomics Approach. BioMed Research International, 2018, 2018, 1-11.	0.9	21

#	ARTICLE	IF	CITATIONS
662	HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. <i>Frontiers in Endocrinology</i> , 2018, 9, 715.	1.5	24
663	A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients. <i>BMC Cancer</i> , 2018, 18, 1178.	1.1	16
664	Magneto-resistive biosensors with on-chip pulsed excitation and magnetic correlated double sampling. <i>Scientific Reports</i> , 2018, 8, 16493.	1.6	13
665	The implementation of omics technologies in cancer microbiome research. <i>Ecancermedicalscience</i> , 2018, 12, 864.	0.6	13
666	Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. <i>Journal of Ovarian Research</i> , 2018, 11, 88.	1.3	26
667	CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 14725.	1.6	35
668	Artificial intelligence in healthcare. <i>Nature Biomedical Engineering</i> , 2018, 2, 719-731.	11.6	1,437
669	Tissue and plasma proteomics for early stage cancer detection. <i>Molecular Omics</i> , 2018, 14, 405-423.	1.4	28
670	The cancer proteomic landscape and the HUPO Cancer Proteome Project. <i>Clinical Proteomics</i> , 2018, 15, 4.	1.1	21
671	Ovarian cancer screening—ultrasound; impact on ovarian cancer mortality. <i>British Journal of Radiology</i> , 2018, 91, 20170571.	1.0	25
672	Potential of mid-infrared spectroscopy as a non-invasive diagnostic test in urine for endometrial or ovarian cancer. <i>Analyst, The</i> , 2018, 143, 3156-3163.	1.7	59
673	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1836-1850.	2.5	42
674	Recent advances in microfluidic methods in cancer liquid biopsy. <i>Biomicrofluidics</i> , 2019, 13, 041503.	1.2	39
675	Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 182.	1.8	55
676	In-silico molecular characterization and mutational analysis of inter-alpha-trypsin inhibitor heavy chain 4 in rheumatoid arthritis. <i>Journal of Proteins and Proteomics</i> , 2019, 10, 313-323.	1.0	1
677	An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4938.	1.8	10
678	Oncoproteomics: Current status and future opportunities. <i>Clinica Chimica Acta</i> , 2019, 495, 611-624.	0.5	20
679	Multiplexed immunophenotyping of circulating exosomes on nano-engineered ExoProfile chip towards early diagnosis of cancer. <i>Chemical Science</i> , 2019, 10, 5495-5504.	3.7	118

#	ARTICLE	IF	CITATIONS
680	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019, 220, 940-950.	1.9	3
681	Plasmonic metaresonances: harnessing nonlocal effects for prospective biomedical applications. <i>Journal of Physics Condensed Matter</i> , 2019, 31, 325301.	0.7	9
682	Urine Biomarkers for the Early Detection of Ovarian Cancer –“ Are We There Yet?. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1983097.	3.6	40
683	Pre- and Post-analytical Factors in Biomarker Discovery. <i>Methods in Molecular Biology</i> , 2019, 1959, 1-22.	0.4	7
684	The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 162, 121-140.	0.9	21
685	Tumour biomarkers –“Tracing the molecular function and clinical implication. <i>Cell Proliferation</i> , 2019, 52, e12589.	2.4	26
686	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400.	0.7	17
687	Supercharging and multiple reaction monitoring of high-molecular-weight intact proteins using triple quadrupole mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2019, 33, 821-830.	0.7	11
688	The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800113.	0.8	88
689	An integrated proteomic and glycoproteomic study for differences on glycosylation occupancy in rheumatoid arthritis. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1331-1338.	1.9	4
690	Univariate and classification analysis reveals potential diagnostic biomarkers for early stage ovarian cancer Type 1 and Type 2. <i>Journal of Proteomics</i> , 2019, 196, 57-68.	1.2	15
691	Visualized Networking of Co-Regulated Lipids in Human Blood Based on High-Throughput Screening Data: Implications for Exposure Assessment. <i>Environmental Science &amp; Technology</i> , 2019, 53, 2862-2872.	4.6	9
692	Enhancing agricultural research within West Africa using sensor-based technologies. <i>African Journal of Agricultural Research Vol Pp</i> , 2019, 14, 1197-1202.	0.2	0
693	Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. <i>Heliyon</i> , 2019, 5, e02826.	1.4	90
694	Using the tools of proteomics to understand the pathogenesis of idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2019, 31, 617-622.	2.0	2
695	<p></p>Serum Apolipoprotein A-I Combined With C-Reactive Protein Serves As A Novel Prognostic Stratification System For Colorectal Cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9265-9276.	0.9	8
696	Cancer biomarker discovery and translation: proteomics and beyond. <i>Expert Review of Proteomics</i> , 2019, 16, 93-103.	1.3	107
697	Mitochondrial DNA deletions accurately detect endometriosis in symptomatic females of child-bearing age. <i>Biomarkers in Medicine</i> , 2019, 13, 291-306.	0.6	17

#	ARTICLE	IF	CITATIONS
698	Salivary Proteomic Analysis of Betel Nut ( <i>Areca catechu</i> ) Consumers by Mass Spectrometry Revealed Primary Indication of Oral Malignancies. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 1073-1084.	0.9	0
699	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	4.3	56
700	Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules. <i>Small Methods</i> , 2020, 4, 1900407.	4.6	22
701	Identification of an Immunoglobulin M (IgM) Antibody Against Enolase 1 Protein (ENO1) Derived from HEK-293 Cells in Patients with Kidney Failure. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 1251-1257.	0.9	0
702	Strategies for Tumor Hypoxia Imaging Based on Aggregation-Induced Emission Fluorogens. <i>Chemistry - A European Journal</i> , 2020, 26, 2521-2528.	1.7	28
703	A novel 8.7-kb mitochondrial genome deletion accurately detects endometriosis in the plasma of symptomatic women. <i>Biomarkers in Medicine</i> , 2020, 14, 97-107.	0.6	2
704	CuO-ZnO heterojunction derived from Cu <sup>2+</sup> -doped ZIF-8: A new photoelectric material for ultrasensitive PEC immunoassay of CA125 with near-zero background noise. <i>Analytica Chimica Acta</i> , 2020, 1099, 75-84.	2.6	35
705	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
706	Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. <i>Journal of Clinical Medicine</i> , 2020, 9, 2010.	1.0	20
707	Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 20071.	1.6	16
708	Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , .	0.2	1
709	A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease. <i>Clinical Proteomics</i> , 2020, 17, 37.	1.1	7
710	NGA-Inspired Nanorobots-Assisted Detection of Multifocal Cancer. <i>IEEE Transactions on Cybernetics</i> , 2022, 52, 2787-2797.	6.2	11
711	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. <i>Statistics in Medicine</i> , 2020, 39, 4405-4420.	0.8	4
712	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2519.	1.7	3
713	Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. <i>Journal of Biophotonics</i> , 2020, 13, e201960235.	1.1	0
714	Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1. <i>Journal of Ovarian Research</i> , 2020, 13, 76.	1.3	22
715	Glycoprotein biomarkers and analysis in chronic obstructive pulmonary disease and lung cancer with special focus on serum immunoglobulin G. <i>Clinica Chimica Acta</i> , 2020, 506, 204-213.	0.5	18

#	ARTICLE	IF	CITATIONS
716	Age-related isomerization of Asp in human immunoglobulin G kappa chain. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140410.	1.1	3
717	The expression of apolipoproteina1 and its correlation with infiltration of urologic neoplasm. <i>Translational Cancer Research</i> , 2020, 9, 690-697.	0.4	0
718	The separation sciences, the front end to proteomics: An historical perspective. <i>Biomedical Chromatography</i> , 2021, 35, e4995.	0.8	9
719	Using proteomic and transcriptomic data to assess activation of intracellular molecular pathways. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 127, 1-53.	1.0	13
720	New Predictive Biomarkers for Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 465.	1.3	38
721	Parasite-derived microRNAs as a diagnostic biomarker: potential roles, characteristics, and limitations. <i>Journal of Parasitic Diseases</i> , 2021, 45, 546-556.	0.4	5
722	Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 1967-1978.	1.2	4
723	Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers. <i>Proteomes</i> , 2021, 9, 25.	1.7	6
724	Quantum Chemistry Calculations for Metabolomics. <i>Chemical Reviews</i> , 2021, 121, 5633-5670.	23.0	47
725	Exploring the Physiological Role of Transthyretin in Glucose Metabolism in the Liver. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6073.	1.8	2
726	Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?. <i>World Journal of Gastroenterology</i> , 2021, 27, 4045-4087.	1.4	38
727	Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. <i>Nature Protocols</i> , 2021, 16, 3737-3760.	5.5	110
728	A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen <i>Gallus gallus</i> . <i>Comparative Medicine</i> , 2021, 71, 271-284.	0.4	3
729	Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma – a prospective trial. <i>BMC Cancer</i> , 2021, 21, 1037.	1.1	8
730	Development of Multi-marker-based Diagnostic Assays with the ProteinChip® System. , 0, , 1325-1342.		1
731	Ovarian Cancer Screening and Early Detection. , 2014, , 33-58.		2
732	The Human Plasma and Serum Proteome. , 2007, , 195-224.		7
733	SELDI Technology for Identification of Protein Biomarkers. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 251-271.	0.1	2



#	ARTICLE	IF	CITATIONS
734	A Novel Approach Using MALDI-TOF/TOF Mass Spectrometry and Prestructured Sample Supports (AnchorChip Technology) for Proteomic Profiling and Protein Identification. <i>Methods in Molecular Biology</i> , 2008, 441, 57-70.	0.4	18
735	Statistical Contributions to Proteomic Research. <i>Methods in Molecular Biology</i> , 2010, 641, 143-166.	0.4	17
736	Purification and Identification of Candidate Biomarkers Discovered Using SELDI-TOF MS. <i>Methods in Molecular Biology</i> , 2012, 818, 49-66.	0.4	4
737	The Use of Metal Oxide Semiconductors for THz Spectroscopy of Biological Applications. <i>IFMBE Proceedings</i> , 2020, , 213-217.	0.2	4
738	Ovarian Cancer Biomarkers: Moving Forward in Early Detection. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1219, 355-363.	0.8	60
739	Proteomic Studies of Micronutrient Deficiency and Toxicity. , 2020, , 257-284.		8
740	Does the Serum Peptidome Reveal Hemostatic Dysregulation?. , 2007, , 23-44.		13
741	Prevention and Early Detection of Ovarian Cancer: Mission Impossible?. <i>Recent Results in Cancer Research</i> , 2007, 174, 91-100.	1.8	92
743	Biomarkers for Cancer Diagnostics. , 2008, , 277-282.		4
744	Proteomics: methodologies and applications to the study of human diseases. <i>Revista Da Associação MÃ©dica Brasileira</i> , 2012, 58, 366-375.	0.3	4
745	Pig Major Acute-Phase Protein and apolipoprotein A-I responses correlate with the clinical course of experimentally induced African Swine Fever and Aujeszky's disease. <i>Veterinary Research</i> , 2007, 38, 741-753.	1.1	35
746	Plasma Proteome to Look for Diagnostic Biomarkers of Early Bacterial Sepsis after Liver Transplantation. <i>Anesthesiology</i> , 2010, 112, 926-935.	1.3	28
747	Proteomic identification and profiling of canine lymphoma patients. <i>Veterinary and Comparative Oncology</i> , 2009, 7, 92-105.	0.8	25
748	Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. <i>Journal of Clinical Investigation</i> , 2005, 116, 26-30.	3.9	219
749	Increased Phosphorylation of Vimentin in Noninfiltrative Meningiomas. <i>PLoS ONE</i> , 2010, 5, e9238.	1.1	46
750	Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. <i>PLoS ONE</i> , 2015, 10, e0141876.	1.1	87
751	An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. <i>Journal of Zhejiang University Science B</i> , 2005, 6B, 227-231.	0.4	25
752	Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer. <i>Oncotarget</i> , 2017, 8, 71965-71980.	0.8	26

#	ARTICLE	IF	CITATIONS
753	Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. <i>Oncotarget</i> , 2016, 7, 7216-7226.	0.8	29
754	Relationship between inter- $\alpha$ -trypsin inhibitor heavy chain 4 and ovarian cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 955-964.	0.7	9
755	Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology. <i>Current Pharmaceutical Design</i> , 2014, 20, 49-55.	0.9	22
756	Comparative 2-DE proteomic analysis clarified that the stability of ITIH-4 is decreased under the storage at 4°C. <i>Journal of Electrophoresis</i> , 2006, 50, 13-17.	0.2	1
757	Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry. <i>Blood Transfusion</i> , 2010, 8 Suppl 3, s98-104.	0.3	3
758	Ovarian Cancer Screening. , 2008, , 45-64.		2
759	Discovering differential protein expression caused by CagA-induced ERK pathway activation in AGS cells using the SELDI-ProteinChip platform. <i>World Journal of Gastroenterology</i> , 2008, 14, 554.	1.4	9
760	Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption/ionisation-time of flight mass spectrometry. <i>World Journal of Gastroenterology</i> , 2006, 12, 1536.	1.4	132
761	New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. <i>World Journal of Gastroenterology</i> , 2006, 12, 7604.	1.4	42
762	Moving forward in colorectal cancer research, what proteomics has to tell. <i>World Journal of Gastroenterology</i> , 2007, 13, 5813.	1.4	18
763	Clustering Mass Spectral Peaks Increases Recognition Accuracy and Stability of SVM-based Feature Selection. <i>Journal of Proteomics and Bioinformatics</i> , 2010, 03, 048-054.	0.4	5
764	Early Diagnosis of Gynecological Cancers in Ladies with Review of Literature. <i>Open Journal of Obstetrics and Gynecology</i> , 2017, 07, 520-524.	0.1	1
765	Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2010, 2, 127.	0.8	13
766	Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. <i>International Journal of Biological Markers</i> , 2007, 22, 281-286.	0.7	15
767	Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. <i>International Journal of Biological Markers</i> , 2007, 22, 172-180.	0.7	8
769	Considerations for the Use of Blood Plasma and Serum for Proteomic Analysis. <i>Internet Journal of Genomics and Proteomics</i> , 2005, 1, .	0.2	7
770	Protein signatures linking history of miscarriages and metabolic syndrome: a proteomic study among North Indian women. <i>PeerJ</i> , 2019, 7, e6321.	0.9	4
771	Proteomic Biomarkers for Early Detection and Patients's Stratification in Ovarian Cancer: A Brief Overview. , 2021, , 187-202.		1

#	ARTICLE	IF	CITATIONS
773	Emerging Role of Inhibin as a Biomarker for Ovarian Cancer. <i>Women's Health</i> , 2005, 1, 51-57.	0.7	1
774	Proteomic Analysis of Surrogate Tissues. , 2005, , 93-107.		1
775	Three Biomarkers Identified From Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. <i>Yearbook of Pathology and Laboratory Medicine</i> , 2006, 2006, 117-118.	0.0	0
776	Molecular biomarkers: new approaches in ovarian cancer diagnosis. <i>Biopolymers and Cell</i> , 2006, 22, 403-424.	0.1	0
777	Le ph�notype biologique du potentiel m�tastatique des cancers du sein existe-t-il ? , 2007, , 27-46.		0
778	New Developments in Proteomics. <i>North Carolina Medical Journal</i> , 2007, 68, 119-122.	0.1	0
779	Protein Microarray Technology. <i>Springer Protocols</i> , 2008, , 451-461.	0.1	0
781	Activity Based Proteomic Profiling of Lysophosphatidic Acid Treated Cancer Cells. <i>Vanderbilt Undergraduate Research Journal</i> , 0, 4, .	0.0	0
782	DNA Methylation in Tumor Diagnosis. , 2008, , 319-332.		0
783	Whole-Genome Analysis of Cancer. , 2009, , 1-30.		0
784	Proteomic Methods in Cancer Research. , 2009, , 1-27.		0
785	MOLECULAR AND BIOLOGICAL DIAGNOSIS OF EARLY GYNECOLOGIC CANCERS. , 2008, , 267-284.		0
786	Efficiency of Canonical Discriminant Function versus Mahalanobis Distance in Differentiating Groups: Screening Ovarian Cancer in a Multivariate System Analysis Using Enzyme Markers. <i>Journal of Modern Applied Statistical Methods</i> , 2009, 8, 306-315.	0.2	1
787	Ovarian Cancer Screening. , 2010, , 87-107.		0
790	Evaluation of Relationship Between Serum Protein Profiles and Lung Cancer by SELDI-TOF-MS (Surface) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Journal of Medical Sciences</i> , 2012, 32, 1084-1089.	0.1	0
791	Tumor Markers. , 2012, , 617-667.		1
792	Prot�omique et cancer du sein: Techniques et perspectives. , 2012, , 291-307.		0
793	Comparative Proteomics: An Approach to Elucidating the Function of a Novel Gene Called BRE. , 0, , .		0

#	ARTICLE	IF	CITATIONS
795	æ-°ã-ã,å•è,,^çj-àCE-ã@ãfã,ã,ãfžãf1/4ã,«ãf1/4é-ç™º : æ-°ã-ã,ãf-ãfãfã,ãf1/4ãfæŠèj“ã,ç”ã,ãj (3.ã•è,,^çj-àCE-ã@ãfã,ã,ãfžãf1/4ã,«ãf1/4é-ç™º		
796	Sample Preparation and Profiling: Biomarker Discovery in Body Fluids by Proteomics. RSC Drug Discovery Series, 2013, , 113-135.	0.2	0
797	Proteomic Analyses of Post-Translational Modifications. , 2013, , 59-80.		0
798	OMICS for Tumor Biomarker Research. , 2014, , 1-22.		0
799	The potentialities proteomic analysis of ocular fluids and tissues in different ophthalmic disorders. Ophthalmology Journal, 2016, 9, 29-37.	0.1	0
800	Biomarkers for Recurrence of Hepatocellular Carcinoma. Biomarkers in Disease, 2017, , 167-191.	0.0	0
801	The Role of Circulating Antigen and Autoantibody in Diagnosing Ovarian Cancer. International Journal for Research in Applied Science and Engineering Technology, 2017, V, 1568-1573.	0.1	0
802	The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer. International Journal of Cancer Management, 2018, 11, .	0.2	2
803	Prealbumin and Retinol Binding Protein as Screening Tools for Malnutrition. , 2019, , 683-703.		0
804	Biosensors and its Applications for Early Detection of Gastrointestinal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 133-168.	0.2	0
807	Molecular Markers in Epithelial Ovarian Cancer. , 2007, , 29-47.		0
808	Proteomics of Pleural Effusion. , 2007, , 285-307.		0
809	Clinical proteomics: present and future prospects. Clinical Biochemist Reviews, 2006, 27, 99-116.	3.3	55
810	A new approach for the analysis of mass spectrometry data for biomarker discovery. AMIA ... Annual Symposium proceedings, 2006, , 26-30.	0.2	2
811	Reproducibility of retention time using a splitless nanoLC coupled to an ESI-FTICR mass spectrometer. Journal of Biomolecular Techniques, 2005, 16, 414-22.	0.8	1
812	Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF. Journal of Biomolecular Techniques, 2006, 17, 145-56.	0.8	23
813	Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21. Cancer Informatics, 2007, 2, 44-7.	0.9	1
814	Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Informatics, 2007, 3, 295-305.	0.9	5

#	ARTICLE	IF	CITATIONS
815	Identifying biomarkers from mass spectrometry data with ordinal outcome. <i>Cancer Informatics</i> , 2007, 3, 19-28.	0.9	10
816	A list of candidate cancer biomarkers for targeted proteomics. <i>Biomarker Insights</i> , 2007, 1, 1-48.	1.0	222
817	Proteomics and mass spectrometry for cancer biomarker discovery. <i>Biomarker Insights</i> , 2007, 2, 347-60.	1.0	10
818	Validation of candidate serum ovarian cancer biomarkers for early detection. <i>Biomarker Insights</i> , 2007, 2, 369-75.	1.0	37
819	Automatic selection of preprocessing methods for improving predictions on mass spectrometry protein profiles. <i>AMIA ... Annual Symposium proceedings</i> , 2010, 2010, 632-6.	0.2	0
820	Differential expression of proteins in monozygotic twins with discordance of infantile esotropic phenotypes. <i>Molecular Vision</i> , 2011, 17, 1618-23.	1.1	4
821	An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers. <i>Reviews in Obstetrics and Gynecology</i> , 2012, 5, 35-41.	0.7	32
823	Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies. <i>Facts, Views &amp; Vision in ObGyn</i> , 2015, 7, 42-59.	0.5	8
824	Role of MAPK7 in cell proliferation and metastasis in ovarian cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 10444-51.	0.5	9
825	Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry. <i>American Journal of Cancer Research</i> , 2016, 6, 1828-36.	1.4	9
826	Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2020, 13, S113-S121.	0.6	0
827	Emerging on-chip electrokinetic based technologies for purification of circulating cancer biomarkers towards liquid biopsy: A review. <i>Electrophoresis</i> , 2022, 43, 288-308.	1.3	7
828	THz Spectroscopy by Narrow Spectral Emission of Quantum Cascade Lasers for Medical Applications. , 2021, , .		2
829	Ovarian cancer detection using optical coherence tomography and convolutional neural networks. <i>Neural Computing and Applications</i> , 2022, 34, 8977-8987.	3.2	12
830	Proteomic-based identification of novel biomarkers. , 2022, , 131-151.		0
831	Proteomics technologies for cancer liquid biopsies. <i>Molecular Cancer</i> , 2022, 21, 53.	7.9	70
832	Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer. <i>Cells</i> , 2022, 11, 973.	1.8	9
833	Proteomics for Diagnostic Applications. , 2006, , 337-348.		0

#	ARTICLE	IF	CITATIONS
836	Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. <i>Proteomes</i> , 2022, 10, 16.	1.7	66
837	The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy. <i>Diagnostics</i> , 2022, 12, 1212.	1.3	4
838	Prospects of using proteome technologies in the diagnostics of sexually transmitted infections and skin diseases. <i>Vestnik Dermatologii i Venerologii</i> , 2010, 86, 17-27.	0.2	0
840	Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area. <i>Journal of Proteome Research</i> , 2022, 21, 1718-1735.	1.8	21
842	Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. <i>Cancers</i> , 2022, 14, 2885.	1.7	22
843	Early diagnostics and screening for ovarian cancer. <i>Kazan Medical Journal</i> , 2022, 103, 476-483.	0.1	1
844	Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	3
845	Emerging technologies in cancer detection. , 2022, , 353-392.		1
846	The Role of Three Plasma Proteins in the Diagnosis of Ovarian Tumors. <i>Journal of Biomedical and Clinical Research</i> , 2022, 15, 41-46.	0.1	0
847	Defining the Role of Mass Spectrometry in Cancer Diagnostics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1555-1557.	1.1	12
848	Plasma Protein Profiling by Mass Spectrometry for Cancer Diagnosis: Opportunities and Limitations. <i>Clinical Cancer Research</i> , 2005, 11, 963-965.	3.2	92
849	Protein glycosylation in urine as a biomarker of diseases. <i>Translational Research</i> , 2023, 253, 95-107.	2.2	7
850	Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. <i>Genes and Diseases</i> , 2023, 10, 1005-1018.	1.5	4
851	Allosteric aptasensor-initiated target cycling and transcription amplification of light-up RNA aptamer for sensitive detection of protein. <i>Sensors and Actuators B: Chemical</i> , 2022, 371, 132526.	4.0	5
852	Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , .	1.0	2
853	OMICS in Schizophrenia and Alzheimer's Disease. , 2022, , 109-119.		0
854	Salivary biomarkers in cancer. <i>Advances in Clinical Chemistry</i> , 2022, , 171-192.	1.8	3
856	Diagnosis and subtype classification on serum peptide fingerprints by mesoporous polydopamine with built-in metal-organic framework. <i>Chinese Chemical Letters</i> , 2023, 34, 107829.	4.8	5

#	ARTICLE	IF	CITATIONS
857	Ovarian Cancer Biomarkers. , 2022, , 27-42.		3
858	The issues and challenges with cancer biomarkers. Journal of Cancer Research and Therapeutics, 2023, 19, 20.	0.3	2
859	Comparative proteome analysis reveals possible heterosis for growth, immunity and antioxidation mechanisms in <i>Macrobrachium nipponense</i> hybrid offspring and parent populations. Aquaculture Research, 2022, 53, 6878-6889.	0.9	0
860	The Endometriotic Neoplasm Algorithm for Risk Assessment (e-NARA) Index Sheds Light on the Discrimination of Endometriosis-Associated Ovarian Cancer from Ovarian Endometrioma. Biomedicines, 2022, 10, 2683.	1.4	3
862	The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity. Diagnostics, 2022, 12, 2985.	1.3	13
863	Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice. Proteomes, 2023, 11, 2.	1.7	3
864	The prognosis predictive score around primary debulking surgery (PPSP) improves diagnostic efficacy in predicting the prognosis of ovarian cancer. Scientific Reports, 2022, 12, .	1.6	2
865	Personalized medicine. , 2023, , 1-32.		0
866	Cancer proteomics: Application of case studies in diverse cancers. , 2023, , 219-239.		0
867	Frontiers in mass spectrometryâ€‘based clinical proteomics for cancer diagnosis and treatment. Cancer Science, 2023, 114, 1783-1791.	1.7	6
868	The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours. Journal of Obstetrics and Gynaecology, 2022, 42, 3441-3449.	0.4	3
869	Proteomic Applications and Considerations: From Research to Patient Care. Methods in Molecular Biology, 2023, , 181-192.	0.4	0
870	Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?. Biomedicines, 2023, 11, 652.	1.4	4
871	A reflex testing protocol using two multivariate index assays improves the risk assessment for ovarian cancer in patients with an adnexal mass. International Journal of Gynecology and Obstetrics, 2023, 162, 485-492.	1.0	0
872	Applications of mass spectroscopy in understanding cancer proteomics. , 2023, , 179-204.		0
873	Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients. Journal of Inflammation Research, 0, Volume 16, 1227-1241.	1.6	2
878	Biomarkers for Recurrence of Hepatocellular Carcinoma. Biomarkers in Disease, 2015, , 1-25.	0.0	0
880	Proteomics in Oncology: Retrospect and Prospects. , 2023, , 243-269.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------